[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 192
1. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood; 2005 Feb 1;105(3):948-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.
  • In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h).
  • Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate tumor mass MTX can be reduced from 5 g/m(2) to 1 g/m(2).
  • For patients in R2, event-free survival (pEFS) was 95% +/- 2% (n = 222) in NHL-BFM95 (MTX 1 g/m(2)) and 97% +/- 1% (n = 154) in NHL-BFM90 (MTX 5 g/m(2)).
  • MTX-4h was noninferior to MTX-24h for limited stage B-cell non-Hodgkin lymphoma (B-NHL) but not for advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Methotrexate / administration & dosage. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Survival Analysis. Time Factors

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486066.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L: An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer; 2005 Mar 1;103(5):978-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
  • BACKGROUND: In a previous study, the authors demonstrated that the combination of pentostatin (P) and rituximab (R) was well tolerated and was active in patients with low-grade non-Hodgkin lymphoma (NHL).
  • METHODS: Twenty-four previously untreated patients with histologically proven, Stage III or IV, low-grade NHL were registered between April and September, 2002.
  • Eighty-three percent of patients had Stage IV disease, the median patient age was 62 years (range, 4-81 years), and the performance status was 0-2.
  • CONCLUSIONS: In this study, PMR was active and well-tolerated in patients with low-grade NHL, and the combination is deserving of further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin. Male. Middle Aged. Mitoxantrone / administration & dosage. Pentostatin / administration & dosage. Pilot Projects. Rituximab. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15672388.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


3. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, Iacoviello L, Donati MB: Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood; 2010 Jul 1;115(26):5322-8
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.
  • In this meta-analysis we sought to obtain accurate estimates of the thrombotic risk in lymphoma patients.
  • The IR of thrombosis observed in subjects with non-Hodgkin lymphoma (NHL) was 6.5% (95% CI, 6.1%-6.9%), significantly greater than that observed for patients with Hodgkin lymphoma (4.7%; 95% CI, 3.9%-5.6%).
  • Within NHL, patients with high-grade disease had a greater risk of events (IR 8.3%; 95% CI, 7.0%-9.9%) than low-grade disease (IR 6.3%; 95% CI, 4.5%-8.9%).
  • This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease.
  • These results may help better defining lymphoma populations at high thrombotic risk, to whom prophylactic approaches could be preferentially applied.
  • [MeSH-major] Lymphoma / complications. Thrombosis / complications. Thrombosis / epidemiology
  • [MeSH-minor] Adult. Cohort Studies. Hodgkin Disease / complications. Humans. Lymphoma, Non-Hodgkin / complications. Risk

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378755.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Dembowska-Baginska B, Perek D, Brozyna A, Wakulinska A, Olczak-Kowalczyk D, Gladkowska-Dura M, Grajkowska W, Chrzanowska KH: Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer; 2009 Feb;52(2):186-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS).
  • BACKGROUND: Due to small number of patients with Nijmegen Breakage Syndrome (NBS) and Non-Hodgkin lymphoma (NHL) experience in their treatment is limited.
  • PROCEDURE: Since 1996, 17 patients with a median age of 9.5 years who had NBS, were treated for NHL.
  • NHL type, stage, chemotherapy, dose modifications, chemotherapy delays, response to chemotherapy, toxicity, outcome and correlation of drug reduction with response to treatment and outcome were analyzed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Nijmegen Breakage Syndrome / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Humans. Male. Remission Induction. Retrospective Studies. Treatment Outcome. Young Adult


5. Al-Sayes FM: Gastrointestinal Non-Hodgkin's lymphoma: a clinico-pathological study. Saudi J Gastroenterol; 2006 Sep-Dec;12(3):118-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal Non-Hodgkin's lymphoma: a clinico-pathological study.
  • OBJECTIVES: The aim of this study is to determine the clinico-pathological features of primary gastrointestinal non-Hodgkin's lymphoma (GI NHL) at King Abdulaziz University Hospital, Jeddah, and to compare our results to those reported in the literature.
  • MATERIALS AND METHODS: Twenty-three adult patients with primary GI NHL diagnosed over a 5-year period (2000 through 2005) were retrospectively studied clinically and histopathologically.
  • RESULTS: Of the 23 patients with primary GI NHL, 14 (60.9%) were Saudis, with a male-to-female ratio of 1.3:1.
  • The most frequent histologic subtype was the diffuse large B cell lymphoma, accounting for 60.9% of all cases, followed by the marginal-zone cell lymphoma (MALT type), which was Helicobacter pylori associated (39.1%).
  • A large proportion of patients with primary GI NHL had early disease (Stage IE - 20%, Stage IIE - 58.6%).
  • CONCLUSION: The data demonstrated that primary GI NHL is more common among males, mainly in their sixth decade.
  • Diffuse large B cell lymphoma is the most frequent histologic subtype, followed by extranodal marginal-zone B cell lymphoma (MALT type), which was Helicobacter-associated.
  • A majority of cases have early disease (stage IE and IIE), mostly treated by combination chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858597.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


6. Zvonkov EE, Krasil'nikova BB, Makhinia VA, Kaplanskaia IB, Kravchenko SK, Karagiulian SR, Grzhimolovskiĭ AV, Kuznetsov AN, Magomedova AU, Shukhman IM, Bariakh EA, Giliazitdinova EA, Gubkin AV, Lorie IuIu, Kremenetskaia AM, Vorob'ev AI: [First experience with the modified program NHL-BFM-90 application in adult patients with primary diffuse large B-cell gastric lymphosarcoma with unfavourable prognosis]. Ter Arkh; 2006;78(7):38-46
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [First experience with the modified program NHL-BFM-90 application in adult patients with primary diffuse large B-cell gastric lymphosarcoma with unfavourable prognosis].
  • AIM: To assess efficacy of a modified program NHL-BFM-90 in adult patients with primary diffuse large B-cell gastric lymphosarcoms (PDLBGL) with unfavourable prognosis.
  • MATERIAL AND METHODS: Modified courses of NHL-BFM-90 were conducted in 5 patients aged 27-67 years from January 2004 to September 2005.
  • All the patients were in a severe clinical condition and had several initial factors of unfavourable prognosis: size of the tumor more than 10 cm; stage IE and more advanced; B-symptoms; proliferative activity above 70%.
  • The program NHL-BFM-90 was modified because of the patients' age.
  • Chemotherapy was conducted according to the middle arm of the original program NHL-BFM-90, but methotrexate was introduced in a dose 1 g/m2 for 12 hours, while leukovorin was given 18 hours after the start of methotrexate injection.
  • A total of 23 modified blocks NHL-BFM-90 were performed: one patient was given 6 blocks, two patients--5, one patient--4 blocks and one patient--3 blocks.
  • RESULTS: Four patients after block 2 and one patient after block 3 of polychemotherapy NHL-BFM-90 achieved remission of the disease of 6 to 22 months duration which still continues.
  • CONCLUSION: Treatment according to the modified program NHL-BFM-90 in adult patients with PDLBGL and unfavourable prognosis is highly effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Schedule. Endoscopy, Gastrointestinal. Female. Humans. Middle Aged. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944749.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


7. Batuecas Caletrío A, Gómez González JL, Muñoz Herrera A, Blanco Pérez P, Serradilla López JM, Gil Melcón M, Ocio San Miguel EM: [Non Hodgkin's lymphoma in the ENT field]. Acta Otorrinolaringol Esp; 2005 May;56(5):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non Hodgkin's lymphoma in the ENT field].
  • OBJECTIVES: Non Hodgkin's lymphoma (NHL) is a frecuent tumor in the ENT field althougt there are not too many publications with a large number of patients.
  • PATIENTS AND METHODS: We have studied 300 patiens with NHL and analysed the head and neck affectation, the presence in Waldeyer's ring, the first symptoms and the stage of the disease.
  • CONCLUSION: There is an evident relationship between NHL and the Oto-Rhino-laringology area and it is necessary consider it in the differential diagnosis of head and neck adenopathies.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Otorhinolaryngologic Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15960125.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Magomedova AU, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Bariakh EA, Margolin OV, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Obukhova TN, Moiseeva TN, Zybunova EE, Gemdzhian EG, Vorob'ev AI: [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma]. Ter Arkh; 2006;78(10):44-7
Genetic Alliance. consumer health - Lymphosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].
  • AIM: To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).
  • MATERIAL AND METHODS: A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005.
  • CONCLUSION: The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180937.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


9. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Morozova AK, Zvonkov EE, Kremenetskaia AM, Magomedova AU, Obukhova TN, Mamonov VE, Bariakh EA, Gubkin AV, Lukina AI, Iliushkina EA, Fink OS, Perestoronina TN, Kravchenko SK: [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis]. Ter Arkh; 2009;81(7):61-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis].
  • AIM: To evaluate efficacy of intensive modified program NHL-BFM-90 (mNHL-BFM-90) in adult poor-prognosis patients with diffuse large B-cell lymphosarcoma (DLBCL) of the bones and soft tissues.
  • One patient had stage IE by Ann-Arbor, two--stage IIE (involvement of regional lymph nodes), two--stage ME (multiple bone lesions).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708576.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


11. Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol; 2005 Jul;84(7):462-73
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Between 1990 and 2001, 68 patients with advanced Hodgkin's disease (HD) and 86 patients classified as low-/intermediate-grade B non-Hodgkin's lymphoma (NHL) were reported to the Austrian Stem Cell Transplantation Registry (ASCTR).
  • Overall survival for NHL patients was 45% (95% CI: 26-64%) with a disease-/progression-free survival of 26% at 7 years.
  • In the multivariate Cox regression analysis stage of disease at time of SCT was the most powerful parameter for overall survival, disease-/progression-free survival and relapse.
  • Mantle cell lymphoma, greater than or equal to three lines of previous therapy, and a conditioning regimen other than BEAM were also predictive for death.
  • [MeSH-minor] Adolescent. Adult. Austria. Child. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Recurrence. Registries. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726362.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol; 2005 Oct 1;23(28):7050-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
  • PURPOSE: In the prospective study 02/96 on primary GI lymphoma, we have collected data on histology, clinical features, and treatment results.
  • In particular, in stages I and II localized primary gastric lymphoma (PGL), our objectives were to reduce treatment intensity and to confirm our hypothesis from study 01/92, which maintained that an organ-preserving approach is not inferior to primary surgery.
  • PATIENTS AND METHODS: Patients receiving radiotherapy and/or chemotherapy were stratified for histologic grade, stage, and whether surgery had been carried out or not (as decided by each participating center).
  • The volume depended on stage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma / drug therapy. Lymphoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jun 10;24(17):2682; author reply 2682-3 [16763284.001]
  • (PMID = 16129843.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Amitay-Layish I, David M, Kafri B, Barzilai A, Feinmesser M, Hodak E: Early-stage mycosis fungoides, parapsoriasis en plaque, and pregnancy. Int J Dermatol; 2007 Feb;46(2):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage mycosis fungoides, parapsoriasis en plaque, and pregnancy.
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) coincident with pregnancy is rare, and the literature regarding mycosis fungoides (MF), the most common primary cutaneous NHL, and pregnancy is strikingly sparse.
  • RESULTS: Nine women who met the study criteria were identified, seven with early-stage MF and two with PPP.
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Pregnancy. Pregnancy Outcome


14. Ohga S, Nakamura K, Shioyama Y, Sasaki T, Urashima Y, Terashima H, Honda H: Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy. Radiat Med; 2005 May;23(3):156-61
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II non-Hodgkin's lymphoma: results of combined of THP-COP chemotherapy and radiotherapy.
  • PURPOSE: We evaluated the usefulness of radiotherapy plus THP-COP chemotherapy consisting of cyclophosphamide, vincristine, pirarubicin (tetrahydropyranyl adriamycin, THP), and prednisone for stage I and II non-Hodgkin's lymphoma (NHL).
  • PATIENTS AND METHODS: Between October 1998 and October 2001, 32 patients with Stage I or II NHL were treated with THP-COP plus radiotherapy.
  • CONCLUSION: THP-COP plus radiotherapy appeared to be feasible for stage I and II NHL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940061.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.
  • HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm<sup>3</sup>, BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm<sup>3</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wang W, Gao L, Wang LL, Li MY, Li YY, Zhao W, Xu YY, Ding Y, Yu L: [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1204-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of bone marrow involvement by lymphoma cells in patients with B-NHL by using flow cytometry analysis].
  • This study was purposed to investigate the significance of using (FCM) flow cytometry for detection bone marrow involvement by lymphoma cells in untreated patients with B cell non-Hodgkin's lymphoma (B-NHL).
  • Bone marrow samples of 54 patients with B-NHL were analyzed by flow cytometry, morphological method and molecular biology technique.
  • Even in patients with early stage, lymphoma cells still could be detected by FCM in involved bone marrow.
  • It is concluded that the detection of monoclonal B lymphocytes by using FCM has high sensitivity and accuracy in patients with B-NHL.
  • Evaluation whether the bone marrow has been involved by lymphoma cells should be recommend to every patient with B-NHL before chemotherapy and every disease stages.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129261.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Bariakh EA, Zvonkov EE, Kremenetskaia AM, Kravchenko SK, Magomedova AU, Obukhova TN, Samoĭlova RS, Vorob'ev IA, Kaplanskaia IB, Moiseeva TN, Zybunova EE, Lorie IuIu, Chernova NG, Mar'in DS, Egorova EK, Krasil'nikova BB, Gabeeva NG, Vorob'ev AI: [Treatment of adult Berkitt-like lymphoma]. Ter Arkh; 2005;77(7):53-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult Berkitt-like lymphoma].
  • AIM: To compare programs of chemotherapy used in adult Berkitt-like lymphoma (ABLL); to assess efficacy and toxicity of the protocol AblL-M-04.
  • ABLL stage I, II, III and IV was diagnosed in 3, 5, 8 and 15 patients, respectively.
  • 10 patients had diffuse large B-cell lymphoma.
  • 9 patients received 2 to 6 courses of CHOP, 1 patient--6 courses of Pro-Mace-Cytabom, 11 patients with newly diagnosed ABLL and 5 pretreated with CHOP--NHL-BFM-90.
  • 5 patients on the protocol NHL-BFM-90 died after short-term improvement.
  • Of 10 patients with newly diagnosed ABLL treated according to NHL-BFM-90 protocol, remission was achieved in 4 patients, follow-up median--34 months (2-56).
  • CONCLUSION: The protocol ABLL-M-04 seems to be more effective than a classic NHL-BFM-90, but this must be supported by more cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Adult. Asparaginase / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Dose-Response Relationship, Drug. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prednisone / therapeutic use. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116910.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CHOP protocol; PVDA protocol; non-Hodgkin's lymphoma protocol 8503
  •  go-up   go-down


18. Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX: [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Ai Zheng; 2006 Dec;25(12):1543-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
  • BACKGROUND & OBJECTIVE: Nasopharynx is a commonly involved site of non-Hodgkin's lymphoma (NHL), but the differences of clinical characteristics, prognosis, and treatment strategy between B-cell and NK/T-cell nasopharyngeal NHL have seldom been reported.
  • This study was to investigate the clinical manifestations and treatment outcomes of primary B-cell and NK/T-cell nasopharyngeal NHL at early stage, and evaluate the prognostic differences, so as to provide evidences for treatment optimization.
  • METHODS: Clinical data of 80 patients with previously untreated nasopharyngeal NHL at early stage, admitted from May 1987 to Nov.
  • CONCLUSIONS: Among the patients with primary nasopharyngeal NHL at early stage, those with B-cell phenotype may have better prognosis as compared with those with NK/T-cell phenotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Nasopharyngeal Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Immunophenotyping. Lymphoma, Extranodal NK-T-Cell / drug therapy. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Extranodal NK-T-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166383.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Bischof M, Zierhut D, Neuhof D, Karagiozidis M, Treiber M, Roeder F, Debus J, Krempien R: Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy. Ophthalmologica; 2007;221(5):348-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent stage IE non-Hodgkin's lymphoma of the orbit: results after primary radiotherapy.
  • AIMS: Primary non-Hodgkin's lymphoma (NHL) of the orbit is uncommon, representing approximately 8% of extranodal NHLs.
  • Twenty-two patients with indolent stage IE NHL were reviewed retrospectively to analyze the outcome and late effects of primary local radiotherapy.
  • Extranodal mucosa-associated lymphoid tissue lymphoma (n = 15) was the most common histological subtype of NHL, followed by follicular (n = 6) and lymphoplasmacytic lymphoma (n = 1).
  • The 5-year overall survival rate was 89%; there were no lymphoma-related deaths.
  • CONCLUSIONS: Indolent early stage orbital NHL can be controlled with local radiotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Orbital Neoplasms / pathology. Orbital Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cataract / etiology. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiation Dosage. Radiation Injuries / complications. Sjogren's Syndrome / etiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17728558.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. He YF, Zhang YJ, Li YH, Lin TY, Xia YF, Lu TX, Huang HQ, Jiang WQ, Xian CG, He YJ, Guan ZZ: [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases]. Ai Zheng; 2006 Dec;25(12):1538-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
  • BACKGROUND & OBJECTIVE: Primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has unique clinicopathologic features, and optimal treatment regimen remains unclear.
  • This study was to summarize the clinical features, treatment outcomes, and prognostic factors of primary NHL of the nasal cavity at early stage.
  • METHODS: Records of 108 patients with primary NHL of the nasal cavity, consecutively treated at Cancer Center, Sun Yat-sen University from Jun.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Nasal Cavity. Nose Neoplasms. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Proportional Hazards Models. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166382.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


21. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP, Southwest Oncology Group: Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol; 2008 May 10;26(14):2258-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
  • PURPOSE: To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining rituximab with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT).
  • PATIENTS AND METHODS: Southwest Oncology Group (SWOG) study S0014 enrolled patients with newly diagnosed, aggressive, CD20-expressing non-Hodgkin's lymphoma (NHL).
  • Patients had limited-stage disease and at least one adverse risk factor as defined by the stage-modified International Prognostic Index (nonbulky stage II disease, age > 60 years, WHO performance status of 2, or elevated serum lactate dehydrogenase).
  • RESULTS: Sixty patients with aggressive NHL were eligible.
  • CONCLUSION: In limited-stage DLBCL, the addition of rituximab to three cycles of CHOP plus IFRT met prespecified study criteria of efficacy, with 2-year PFS of at least 84%, meriting further investigation.
  • We hypothesize that such a pattern may be the result of biologic differences between limited- and advanced-stage lymphoma.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA04919
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


22. Garavaglia E, Taccagni G, Montoli S, Panacci N, Ponzoni M, Frigerio L, Mangili G: Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients. Gynecol Oncol; 2005 Apr;97(1):214-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients.
  • BACKGROUND: Non-Hodgkin's Lymphomas (NHL) frequently affect the uterine corpus, cervix, and vagina in cases of advanced disease.
  • CASE: Three patients with large B-cell primary Non-Hodgkin's lymphoma of the lower genital tract (vaginal, cervical and cervico-vaginal) presented with bulky lesions and underwent diagnostic evaluation, staging, and chemotherapy with adriamycin-containing regimens.
  • All three patients, including two with stage IIE and one with stage IE disease demonstrated complete remission and are alive and well without evidence of disease at 10, 7, and 6 years of follow-up, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Neoplasms / drug therapy. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Methotrexate / administration & dosage. Neoplasm Staging. Prednisone / administration & dosage. Vincristine / administration & dosage


23. Navarro JT, Ribera JM, Oriol A, Xicoy B, Mate JL, Sirera G, Lloveras N, Millá F, Feliu E: Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy. Int J Hematol; 2007 Nov;86(4):337-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
  • We evaluated the prognostic factors for response and survival in a series of HIV-infected patients with systemic non-Hodgkin's lymphoma (NHL) in the HAART era.
  • Forty patients with systemic NHL treated with a CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) and HAART were studied.
  • A disease stage of III to IV was the only parameter with prognostic influence on DFS.
  • The factors influencing OS were an International Prognostic Index >2, an Eastern Cooperative Ecology Group (ECOG) score >2, and a disease stage of III to IV.
  • Patients with an advanced stage had a lower OS probability in a multivariate analysis (odds ratio, 4.24; 95% CI, 1.24- 14.57).
  • Advanced stage was the main prognostic factor predicting survival in ARL treated with CHOP and HAART.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / pathology. Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. HIV / physiology. Humans. Male. Prednisolone. Prognosis. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055341.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


24. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol; 2005 Feb 20;23(6):1103-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
  • PURPOSE: Patients with newly diagnosed, advanced-stage, follicular grade 1 non-Hodgkin's lymphoma (NHL) are often asymptomatic and can be observed without immediate chemotherapy.
  • PATIENTS AND METHODS: Eligible patients had untreated follicular grade 1 NHL, and measurable stage III/IV disease.
  • CONCLUSION: Rituximab can be safely administered to patients with advanced-stage follicular grade 1 NHL with efficacy and minimal toxicity.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Disease Progression. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Rituximab. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Feb 20;23(6):1056-8 [15657408.001]
  • (PMID = 15657404.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


25. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R: Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol; 2006 Apr 1;24(10):1590-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
  • PURPOSE: To compare the efficacy and safety of fludarabine phosphate with cyclophosphamide, vincristine, and prednisone (CVP) in 381 previously untreated, advanced-stage, low-grade (lg) non-Hodgkin's lymphoma (NHL) patients in a phase III, multicenter study.
  • Combination therapies incorporating fludarabine are now being further evaluated as first-line therapy in follicular NHL.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine Phosphate / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prospective Studies. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575010.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


26. Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL: Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. Eur J Nucl Med Mol Imaging; 2005 Oct;32(10):1225-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
  • PURPOSE: The aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative radioimmunotherapy using 131I-rituximab in previously heavily treated patients with B-cell non-Hodgkin's lymphoma (B-NHL).
  • METHODS: Nine patients with relapsed, refractory or transformed B-NHL received ten radioimmunotherapies.
  • Four non-responders with bulky disease died 4.8+/-2.0 months after therapy.
  • CONCLUSION: Radioimmunotherapy with 131I-rituximab in previously heavily treated B-NHL patients was safe and well tolerated, and four out of ten therapies induced responses.
  • Radioimmunotherapy seems to be an additional therapeutic option in carefully selected therapy-refractory B-NHL patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Pilot Projects. Radiation Injuries / etiology. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Severity of Illness Index. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937686.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 131I-rituximab; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Radiopharmaceuticals
  •  go-up   go-down


27. Omoti CE, Halim NK: Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases. Clin Lab Haematol; 2005 Oct;27(5):302-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphomas in Edo state, Niger Delta region of Nigeria--clinicopathological profile of 205 cases.
  • Non-Hodgkin's lymphoma (NHL) occurred predominantly in young adults (20-39 years).
  • A majority of the patients presented in the advanced stage of the disease (Stages III-IV) according to the Ann Arbor system and a performance status (PS) scale of 2-4.
  • The intermediate grade NHL (41.2%) formed the largest group of which diffuse large cell lymphoma (DLCL) was the most commonly observed histopathologic type followed by the large cell immunoblastic type.
  • [MeSH-major] Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Hematologic Tests. Hodgkin Disease / diagnosis. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178909.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Cvetković Z, Vucić V, Cvetković B, Petrović M, Ristić-Medić D, Tepsić J, Glibetić M: Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol; 2010 Aug;89(8):775-82
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma.
  • The data about the fatty acid (FA) status of non-Hodgkin lymphoma (NHL) patients are poor.
  • Therefore, the aim of this study was to investigate the FA profile of serum phospholipids in NHL patients related to the aggressiveness and clinical stage of NHL.
  • We analyzed the FA profile of serum phospholipids in 47 newly diagnosed, untreated NHL patients and in 29 healthy subjects.
  • Significantly higher (p < 0.001) levels of palmitic (16:0), oleic (18:1 n-9) and arachidonic acids (20:4 n-6), saturated and monounsaturated FA were found in NHL patients, while linoleic acid (18:2 n-6) and the levels of total polyunsaturated FA (PUFA), n-3 PUFA, eicosapentaenoic (20:5 n-3) and docosahexaenoic (DHA, 22:6 n-3) were significantly reduced (p < 0.01).
  • The level of oleic acid in patients with indolent NHL was significantly lower (p < 0.05) than in more aggressive types of disease.
  • Contents of palmitoleic acid, docosatetraenoic (22:4 n-6), and PUFA was lower in very aggressive NHL.
  • According to clinical stage (CS), patients with CS I had significantly higher SFA and lower n-6 FA than other three groups, and group with CS IV showed significantly decreased DHA and n-3 PUFA.
  • Our results showed an abnormal FA profile in serum phospholipids in NHL patients.
  • [MeSH-major] Fatty Acids / blood. Lymphoma, Non-Hodgkin / blood. Phospholipids / blood
  • [MeSH-minor] Adult. Aged. Diet. Female. Humans. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20127484.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Phospholipids
  •  go-up   go-down


29. Aitova LG, Vinogradova IuE, Kaplanskaia IB, Lutsenko IN, Zvonkov EE, Momotiuk KS, Kravchenko SK, Kremenetskaia AM, Vorob'ev AI: [High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma]. Ter Arkh; 2009;81(7):53-7
Genetic Alliance. consumer health - Lymphosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate efficacy of the protocol NHL BFM-90 in the treatment of adult anaplastic large cell lymphosarcoma (ALCL) ALK+ and validity of addition of transplantation of autologous stem hemopoietic cells (ASHC) into first line treatment.
  • MATERIAL AND METHODS: We treated 13 patients with stage III-IV ALCL ALK+.
  • The patients were treated according to the protocol NHL BFM-90.
  • ASHC was made in two patients with the disease stage IV.
  • Two patients at stage IV and poor prognosis had undergone ASHC transplantation.
  • CONCLUSION: ALCL ALK+ is characterized by an aggressive clinical course (11 of 13 patients had stage III-IV), high rate of extranodal lesions.
  • We effectively used ASHC transplantation in the first-line treatment of 2 patients with stage IV of the disease and poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Receptor Protein-Tyrosine Kinases. Remission Induction. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708574.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


30. Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M: Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. Int J Lab Hematol; 2008 Aug;30(4):292-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
  • High costs of molecule-targeted drugs, such as rituximab, ibritumomab, and tositumomab have given rise to an economical issue for treating patients with non-Hodgkin's lymphoma (NHL).
  • In Japan, lenograstim at 2 microg/kg (about 100 microg/body) or filgrastim at 50 microg/m(2) (about 75 microg/body) is commonly administered for patients with NHL after chemotherapy.
  • Therefore, cost-effectiveness is an important issue in treatment for NHL.
  • Patients with advanced-stage NHL who needed chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen with or without rituximab were enrolled in this randomized cross-over trial to investigate the efficacy and safety of low-dose G-CSF.
  • Hence, a low dose of lenograstim might be safe, effective and pharmaco-economically beneficial in patients with advanced-stage NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / economics. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Cross-Over Studies. Female. Filgrastim. Humans. Male. Middle Aged. Neutropenia / drug therapy. Neutropenia / etiology. Recombinant Proteins / administration & dosage. Recombinant Proteins / economics

  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665826.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


31. Jiang XF, Yang KX, Peng ZL, Xu L, Huang Q, Li Q: [Clinicopathologic and immunohistochemical study of primary non-Hodgkin lymphoma of the female genital system]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):222-6
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and immunohistochemical study of primary non-Hodgkin lymphoma of the female genital system].
  • OBJECTIVE: To investigate the clinicopathology and immunophenotype of primary non-Hodgkin lymphoma (NHL) of the female genital system, and to analyze the prognosis of such tumors.
  • METHODS: Clinicopathologic features of 43 cases of primary NHL of the female genital system were studied retrospectively, with the histological classification based on the Classification of Haematopoietic and Lymphoid Tumors (WHO, 2001).
  • (1) Primary lesions: there were 24 cases of lymphoma originating in the ovary, 3 cases in the endometrium, 10 cases in the cervix, 2 cases in the vagina and 4 cases in the vulva. (2) Staging: 12 cases (28%) were in stage I, 9 cases (21%) in stage II, and 22 cases (51%) in stage III. (3) Histological classification: 37 cases (86%) were diffuse large B cell lymphoma (DLBCL), 3 cases were Burkitt lymphoma and the remaining 3 cases were unspecified peripheral T-cell lymphoma according to biopsy, immunophenotype analysis, in-situ-hybridization technique and IgH gene rearrangement detection. (4) Prognosis analysis: increase in the level of lactic acid dehydrogenase, stage III, DLBCL and single operation suggest poor prognosis.
  • CONCLUSIONS: Establishment of the diagnosis of primary NHL of the female genital system is based on biopsy, immunophenotype analysis, in-situ-hybridization technique and IgH gene rearrangement detection, which play important roles in diagnosis and differential diagnosis of the tumor.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers. Female. Humans. Immunohistochemistry. Immunophenotyping. L-Lactate Dehydrogenase. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Polymerase Chain Reaction. Prognosis. Retrospective Studies. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631759.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


32. Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F: Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP. Med Oncol; 2010 Sep;27(3):942-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
  • In aggressive non-Hodgkin lymphoma (NHL), CHOP (cyclophosphamide, vincristine, doxorubicin, prednisolone) regimen has been standard for decades, and rituximab has increased response rates and survival in CD20 positive patients, recently.
  • The aim of this prospective trial was to evaluate the long-term efficacy and toxicity of MINE as a consolidation treatment in aggressive NHL patients who had achieved CR or unproven CR after six cycles of CHOP in the first line setting.
  • Most of the patients had advanced stage (84.2% for stage >3) and high IPI score (79% for IPI score >2).
  • Two patients had grade two neuropathy, one had grade three mucositis and another one had non-neutropenic pneumonia.
  • MINE regimen seems to be effective as a consolidation regimen, especially, in intermediate/high risk patients and has low early and late toxicities, and it warrants to be evaluated in phase III randomised trials with rituximab in CD20 positive aggressive NHL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Fever / chemically induced. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Kaplan-Meier Estimate. Male. Mesna / administration & dosage. Mesna / adverse effects. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Peripheral Nervous System Diseases / chemically induced. Prednisolone / administration & dosage. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787462.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MINE protocol; VAP-cyclo protocol
  •  go-up   go-down


33. Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, Alexandrakis MG: Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol; 2008 Feb;30(1):17-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.
  • Increased angiogenesis has been shown to be a feature of non-Hodgkin lymphomas (NHL).
  • In the current study, the pretreatment levels of circulating molecules related to angiogenesis were determined in 49 B-cell NHL patients and correlated with histological grade, disease stage and prognostic score.
  • Increased levels of VEGF, IL-6 and IL-8 were found in the whole group of untreated patients in comparison with normal controls (P < 0.05), whereas, IL-2 was higher in the subgroup of indolent NHL.
  • However, by stratification into group of responders vs. non-responders pretreatment IL-8 was significantly increased whereas IL-16 was decreased in the subgroup of complete responders.
  • There was no association with disease stage or the International Prognostic Score.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukins / blood. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190463.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


34. Akoum R, Brihi E, Saade M, Hanna T, Chahine G: Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma. J Cancer Res Ther; 2007 Jul-Sep;3(3):143-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominal irradiation for refractory non-Hodgkin's lymphoma.
  • BACKGROUND: Abdominal irradiation, as a part of treatment, is often ignored in the management of refractory non-Hodgkin's lymphoma (NHL).
  • MATERIALS AND METHODS: 27 patients with intraabdominal lymphoma underwent salvage irradiation between 1982 and 2001.
  • Survival rates were significantly better for patients with refractory relapse compared to those with primary refractory lymphoma (P < 0.01).
  • Out-of-field recurrence occurred more frequently in initial stage III and IV disease.
  • CONCLUSION: Salvage radiotherapy for refractory abdominal NHL is a feasible alternative for both follicular and diffuse subtypes and may provide significant palliation and prolongation of survival.
  • It is less effective in patients with primary refractory NHL than in those with refractory relapsed NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Salvage Therapy
  • [MeSH-minor] Abdomen. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079576.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


35. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • METHODS: From January 1995 to December 2000, 121 patients with NHL were treated by CEOP regimen with or without radiotherapy for the involved field.
  • RESULTS: Of these 121 patients, 83 (68.6%) had B-cell NHL and 38(31.4%) peripheral T or NK-cell NHL; 55.
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


36. Krawczuk-Rybak M, Solarz E, Gadomski J, Matysiak M, Wołczyński S: [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):623-30
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spermato- and steroidogenesis in young men treated for non-Hodgkin's and Hodgkin's lymphoma during childhood].
  • AIM: To investigate testicular function (spermato- and steroidogenesis) in adolescents and young men cured of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • MATERIAL AND METHODS: In thirty one patients cured of HL 5.9 +/-3.3 years ago and sixteen--cured of NHL before 5.44y +/-2.9 and in twenty one healthy men, we measured serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone using immunoenzymatic methods and inhibin B (RIA method).
  • Patients with NHL and HL in clinical stage I and IIb, presented normal values of all analyzed parameters.
  • 2. The treatment for HL in IIb, IIIb, IV clinical stage with increasing number of therapeutic protocols, especially together with radiotherapy, led to gonadal dysfunction (increase of FSH, decrease of inhibin B values).
  • Treatment for HL of higher clinical stage leads to gonadal dysfunction, especially of spermatogenesis.
  • 2. The treatment for NHL essentially does not have a gonadotoxic effect.
  • [MeSH-major] Combined Modality Therapy / adverse effects. Gonadotropins, Pituitary / blood. Hodgkin Disease / therapy. Infertility, Male / etiology. Lymphoma, Non-Hodgkin / therapy. Spermatogenesis / drug effects. Spermatogenesis / radiation effects
  • [MeSH-minor] Adolescent. Adult. Child. Enzyme-Linked Immunosorbent Assay. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Male. Neoplasm Staging. Testicular Diseases / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317893.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gonadotropins, Pituitary; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


37. Iwahashi N, Nakatani S, Kakuchi H, Yamagishi M, Fukuchi K, Ishida Y, Hirooka K, Koretsune Y, Ueta C, Shirasaka T, Kitakaze M: Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J; 2005 Feb;69(2):243-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The extensive cardiac and extracardiac involvement shown by various imaging modalities, including echocardiography and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), suggested that she was in the critical stage of non-Hodgkin's lymphoma (NHL).
  • AIDS was treated by highly active-antiretroviral therapy and the NHL was treated by a combination of rituximab-cyclophosphamide-vincristine-doxorubicine-predonisolone.
  • Generally, an AIDS-related cardiac tumor tends to be diagnosed at the late stage of the disease because of its nonspecific clinical findings, resulting in an extremely poor prognosis.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Heart Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Adult. Diagnostic Imaging. Echocardiography. Female. Humans. Positron-Emission Tomography. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671621.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


38. Ko OB, Lee DH, Kim SW, Lee JS, Kim S, Huh J, Suh C: Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience. Korean J Intern Med; 2009 Jun;24(2):128-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience.
  • BACKGROUND/AIMS: Although the incidence of T-cell non-Hodgkin's lymphoma (NHL) is higher in Far East Asia than in Western countries, its incidence and clinical course in Korea are not well-defined.
  • Therefore, we assessed the relative frequency and clinical features of T-cell NHL in Korea.
  • METHODS: We performed a retrospetcive analysis of 586 patients with NHL.
  • RESULTS: 101 (17.2%) had T-cell NHL.
  • The most frequent subtypes of T-cell NHL were extranodal NK/T-cell lymphoma, nasal type (NASAL), peripheral T-cell lymphoma, unspecified type (PTCL-U), and anaplastic large cell lymphoma, T/null cell, primary systemic type (ALCL).
  • Univariate analysis of IPI elements and other clinical features showed that clinical stage and extranodal sites were significant predictors of survival.
  • CONCLUSIONS: The relative frequency of T-cell NHL seems to be decreasing in Korea, although NASAL remains frequent.
  • Large-scale studies are warranted for Korean patients with T-cell NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Female. Humans. Incidence. Kaplan-Meier Estimate. Korea / epidemiology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):923-30 [9378552.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2439-48 [9635538.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2797-804 [15728226.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Sep;15(3):533-47 [12468404.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Hum Pathol. 1983 Sep;14(9):745-72 [6350154.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Jpn J Clin Oncol. 1985 Sep;15(3):517-35 [2997510.001]
  • [Cites] Jpn J Clin Oncol. 1985 Dec;15(4):645-51 [4094097.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):370-80 [8001008.001]
  • (PMID = 19543491.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698621
  • [Keywords] NOTNLM ; Lymphoma / Peripheral / T-cell
  •  go-up   go-down


39. Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N: Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol; 2006 Dec;28(4):326-7
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
  • The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).
  • METHODS: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n=7; stage II, n=4; stage III, n=7; stage IV, n=2) was analyzed using Brookfield DV-II + (USA) machine.
  • RESULTS: Blood viscosity in NHL patients (median: 5.5+/-1.46 miliPascal) inversely correlated with lactatdehydrogenase (LDH) level, international prognostic index (IPI) score, and stage (p=0.02, r=-0.51; p=0.03, r=-0.63; and p=0.04, r=-0.45, respectively) and positively correlated with hemoglobin level (p=0.02, r=0.65)).
  • CONCLUSION: According to our data, blood viscosity may be considered as a follow up marker in NHL patients along with LDH level or sedimentation rate.
  • [MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285120.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


40. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, Martini M, Larocca LM, Voso MT, Leone G: Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol; 2009 Aug;20(8):1408-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.
  • PATIENTS AND METHODS: Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkin's lymphoma (HL), 63 with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkin's lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene.
  • RESULTS: Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all).
  • Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively).

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465421.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / beta-Globins
  •  go-up   go-down


41. Magomedova AU, Kravchenko SK, Kremenetskaia AM, Kaplanskaia IB, Zybunova EE, Samoĭlova RS, Vorob'ev IA, Obukhova TN, Ryzhko VV, Zvonkov EE, Vorob'ev AI: [Primary diffuse large B-cell lymphosarcoma of the spleen]. Ter Arkh; 2007;79(7):62-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of them 14 patients had splenectomy as the first stage of therapy.
  • Because of the presence of several signs of unfavourable prognosis 5 patients under 60 years were given intensive therapy: 4-6 courses of the modified program NHL-BFM-90, 2 of 5 patients received radiotherapy.
  • Complete remission of the disease was achieved in 9 (90%) of 10 patients treated on programs CHOP-21, R-CHOP-21, in 4 of 4 patients on the modified program NHL-BFM-90.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Splenic Neoplasms / diagnosis. Splenic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Cyclophosphamide. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisone. Radiotherapy. Remission Induction. Splenectomy. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17802793.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


42. Witzens-Harig M, Heilmann C, Hensel M, Kornacker M, Benner A, Haas R, Fruehauf S, Ho AD: Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells. Stem Cells; 2007 Jan;25(1):228-35
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
  • Graft engineering by CD34(+) selection of peripheral blood progenitor cells (PBPC) has been used in non-Hodgkin lymphoma (NHL) with the aim to reduce relapse related to tumor cells within the graft.
  • From September 1995 to January 2000, 39 patients with newly diagnosed (n = 31) or relapsed (n = 8) NHL were treated in our institution with myeloablative therapy followed by CD34(+) selected autologous PBPC transplantation.
  • Thirty-one patients were diagnosed with follicular lymphoma, and eight patients with mantle-cell lymphoma.
  • All patients had advanced disease (26% of patients stage III and 74% stage IV, Ann Arbor classification).
  • The probabilities of freedom from progression, overall survival, and event-free survival 4 years after transplantation were 96%, 90%, and 87%, respectively, for patients with follicular lymphoma and 42%, 63%, and 33%, respectively, for patients with mantle-cell lymphoma.
  • [MeSH-major] Antigens, CD34 / blood. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Cell Survival. Female. Follow-Up Studies. Hematopoietic Stem Cell Mobilization. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / cytology. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204607.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


43. Yao B, Li YX, Song YW, Jin J, Liu YP, Wang WH, Wang SL, Sun YT, Yu ZH, Liu XF: [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):58-61
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
  • OBJECTIVE: The optimal treatment for primary non-Hodgkin's lymphoma (NHL) of the nasal cavity remains controversial.
  • METHODS: From January 1996 to December 2002, the clinical data of 129 patients with previously untreated nasal NHL were retrospectively reviewed with all lesions confirmed by pathology.
  • 116 patients were morphologically diagnosed as having nasal NK/T cell lymphoma.
  • The immunophenotype was available in 57 cases and 52 (91.2%) of them were confirmed as NK/T-cell lymphoma.
  • According to the Ann Arbor Staging System, 102 patients had stage I(E), 22 stage II(E), and 5 stage IV(E) disease.
  • Among the 124 patients with stage I(E) and II(E) diseases, 22 patients received radiotherapy alone, 7 chemotherapy alone, and 95 combined modality therapy (CMT).
  • The primary treatment for stage IV(E) patients was chemotherapy with or without radiotherapy to the primary tumor.
  • It was 71.7% and 60.9% for stage I(E), and 70.6% and 47.0% for stage II(E), respectively (P > 0.05).
  • Of the 124 patients with stage I(E) and II(E) disease, 67 patients were treated with radiotherapy alone (22 patients) or radiotherapy followed by chemotherapy (45), whereas 57 were treated with chemotherapy followed by radiotherapy (50) or chemotherapy alone (7).
  • For stage I(E) and II(E) disease, the 5-year OS and DFS were 76.0% and 65.0% for radiotherapy with or without chemotherapy, and 74.4% and 56.2% for chemotherapy followed by radiotherapy.
  • However, 7 stage I(E) and II(E) patients were treated with chemotherapy alone, and 4 of them died of disease progression, with 1-year survival of 26.7%.
  • CONCLUSION: The majority of Chinese patients with primary nasal NHL are NK/T cell in origin.
  • The addition of chemotherapy to radiotherapy did not improve the survival of patients with early stage nasal lymphoma.
  • Radiotherapy is suggested as the primary treatment for stage I(E) and II(E) nasal NK/T cell lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Killer Cells, Natural. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Particle Accelerators. Prednisone / administration & dosage. Radiotherapy, High-Energy. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737624.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


44. Bence Z, Kovács G, Jakab Z, Csóka M, Müller J: [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?]. Magy Onkol; 2008 Dec;52(4):357-62
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].
  • The centres of the Hungarian Paediatric Oncology Network annually take care of 250-300 new patients with childhood cancer, every tenth of them suffering from lymphoma.
  • The aim of our work was to analyse the data of the adolescents (14-19 years) with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), comparing their survival rates with younger patients under fourteen and with the international data.
  • From January 1990 to December 2004 there were 281 children diagnosed with HL and 230 with NHL.
  • Among the HL patients 107, while among the NHL patients 51 were older than 14 years old.
  • In the group of HL the distribution of patients according to the stage was similar in younger and older patients.
  • In the NHL group 55% of the children younger than 14, and 72% of the patients older than 14 years old had advanced stage disease (stage III or IV).
  • The OS of the younger children in the NHL group was 78.2+/-3% at 5 and 10 years, and 77.9+/-6% for the adolescents (n.s.).
  • [MeSH-major] Aging. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Age Distribution. Age Factors. Child. Child, Preschool. Female. Humans. Hungary / epidemiology. Infant. Male. Neoplasm Staging. Survival Analysis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068463.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


45. Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G: Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol; 2007 May;78(5):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
  • BACKGROUND: Several papers have reported an association of high CA125 serum levels with advanced non-Hodgkin's lymphoma (NHL) as well as a relationship between high CA125 values and poor outcome.
  • PATIENTS AND METHODS: Ninety-nine patients with NHL or Hodgkin's disease (HD) underwent serum CA125 assessment at diagnosis.
  • Gender, age, presence of B symptoms, performance status (PS), histology, sites of tumor involvement, presence of effusion, clinical stage, age-adjusted International Prognostic Index, C-reactive protein (CRP), Hb, lactate deshydrogenase (LDH) and beta2-microglobulin were evaluated for their association with serum CA125 levels.
  • RESULTS: CA125 serum levels were elevated in 34% of the patients, including 19% of patients with aggressive NHL, 45% of patients with indolent NHL, and 29% of patients with HD.
  • Univariate analyses showed that CA125 levels correlated with poor PS, the presence of B symptoms, advanced clinical stage, abdominal, bone marrow or mediastinal involvement, presence of effusions, high aaIPI, low Hb levels and high CRP, LDH or beta2-microglobulin levels.
  • In univariate analyses, OS and PFS were affected by age (PFS only), poor PS, B symptoms, advanced clinical stage, bone marrow or abdominal involvement (PFS only), high aaIPI, low Hb, high CRP or beta2-microglobulin levels.
  • CONCLUSION: While CA125 serum level correlates significantly with a number of features associated with more aggressive disease, it does not enhance the performance of standard prognostic markers in the management of patients with NHL or HD.
  • [MeSH-major] CA-125 Antigen / blood. Hodgkin Disease / blood. Lymphoma, Non-Hodgkin / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419741.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


46. Cai S, Cannizzo F Jr, Bullard Dunn KM, Gibbs JF, Czuczman M, Rajput A: The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum. Am J Surg; 2007 Mar;193(3):409-12; discussion 412
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum.
  • BACKGROUND: Gastrointestinal involvement of non-Hodgkin's lymphoma (NHL), although rare, may require surgical intervention.
  • The purpose of the current study was to determine the incidence, presentation, and management of patients with NHL of the colon or rectum.
  • METHODS: Demographic data, signs, symptoms, disease stage, and treatment of patients with a primary gastrointestinal lymphoma treated between 1973 and 2005 were identified.
  • RESULTS: Forty-three of 244 gastrointestinal lymphoma patients (18%) had colon or rectal involvement.
  • CONCLUSIONS: Colorectal involvement by NHL occurred in 18% of patients with gastrointestinal lymphoma.
  • [MeSH-major] Colorectal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Abdominal Pain / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy / statistics & numerical data. Comorbidity. Female. Follow-Up Studies. Gastrointestinal Hemorrhage / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. New York / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320545.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, Alavi A, Tehranipour N, Al-Nahhas A, Fanti S: Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur; 2006;9(1):37-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
  • BACKGROUND: The aim of the study was to evaluate the usefulness of 18F-FDG-PET in patients with gastric lymphoma, in particular those affected by mucosa-associated lymphoid tissue (MALT) type and aggressive gastric non-Hodgkin's lymphoma (NHL).
  • MATERIAL AND METHODS: The study group consists of 15 patients with a previous diagnosis of gastric NHL referred to our PET centres in Bologna Hospital and Rovigo Hospital, Italy, in the period 2003-2004.
  • In 9/15 patients the subsequent histological evaluation was consistent with a gastric MALT lymphoma, while aggressive gastric NHL was diagnosed in the other 6/15.
  • PET scan was carried out in patients with known active disease in order to stage or re-stage disease prior to treatment or in patients in complete clinical remission to monitor disease during follow up.
  • RESULTS: Overall 18F-FDG-PET was true positive in all cases of gastric MALT and non-MALT aggressive NHL with known active disease, while no pathological 18F-FDG uptake was evident in the subjects who were in complete clinical remission.
  • The degree of 18F-FDG uptake (mean SUVmax values) in MALT lymphoma was much less intense in comparison to aggressive gastric NHL, suggesting a prognostic role of SUV calculation in gastric lymphomas.
  • CONCLUSION: Our data demonstrate the significant accuracy of 18F-FDG-PET in detecting active disease in gastric lymphoma of both MALT and non-MALT NHL type.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / radionuclide imaging. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791802.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Sun XF, Liu DG, Zhen ZJ, Chen XQ, Xia Y, Wang ZH, He YJ, Guan ZG: [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of short-term and intensive chemotherapy for the treatment of childhood and adolescent B cell non-Hodgkin's lymphoma].
  • OBJECTIVES: To evaluate the efficacy and toxicity of the B-NHL-BFM-90 protocol in the treatment of Chinese childhood and adolescent B-cell non-Hodgkin's lymphomas (B-NHL).
  • METHODS: Forty-two untreated childhood and adolescent B-NHL were enrolled in the present study.
  • Of them 18 cases were Burkitt's lymphoma, 16 diffuse large B cell lymphoma and 8 anaplastic lymphoma.
  • There were 10 cases in stage II and 32 in stage III/IV.
  • All patients were treated with the B-NHL-BFM 90 (Berlin-Frankfurt- Münster) protocol.
  • 24%, being 100% for stage II and 80.95% for stage III/IV.
  • CONCLUSION: Short term and intensive chemotherapy can improves the efficacy and survival rate of childhood and adolescent B-NHL, especially for advanced stage patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Feasibility Studies. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532964.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Valković T, Duletić-Načinović A, Stifter S, Hasan M, Hadžisejdić I, Zombori D, Grahovac B, Jonjić N: Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma. Clin Exp Med; 2010 Dec;10(4):229-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) is one of the most common malignancies whose incidence increases, and the treatment results are not satisfactory.
  • The aim of this study was to determine the capacity of NHL to produce MCP-1, chemokine that induces chemotaxis of macrophages and lymphoid cells.
  • The mRNA expression and protein MCP-1 expression were determined in the samples of 20 patients with NHL and 8 reactive tonsils.
  • MCP-1 mRNA was detected in 8/8 tonsils and in 19/20 patients with NHL by real-time PCR analysis.
  • In addition, the amount of detected MCP-1 cDNA was significantly higher in patients with limited stage, good IPI, normal level of fibrinogen and LDH.
  • Finally, in patients with aggressive NHL, the level of MCP-1 cDNA was higher than in indolent tumours.
  • Moderate cytoplasmic MCP-1 expression was also observed in reactive lymphocytes, while tumour cells of indolent NHL were mostly pale in comparison with aggressive lymphomas which predominantly demonstrated intense MCP-1 staining.
  • [MeSH-major] Chemokine CCL2 / biosynthesis. Gene Expression Profiling. Lymphoma, Non-Hodgkin / pathology. RNA, Messenger / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / chemistry. Female. Humans. Immunohistochemistry. Lymphocytes / chemistry. Macrophages / chemistry. Male. Middle Aged. Palatine Tonsil / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232106.001).
  • [ISSN] 1591-9528
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / RNA, Messenger
  •  go-up   go-down


50. Toda K, Shibuya H, Hayashi K, Ayukawa F: Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study. Radiat Oncol; 2009;4:21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study.
  • BACKGROUND: survivors of non-Hodgkin's lymphoma (NHL) are well known to be at an increased risk of second malignancies.
  • In this study, we evaluated the incidence and clinical features of head and neck cancer (HNC) occurring after radiotherapy (RT) for NHL.
  • MATERIALS AND METHODS: We investigated the clinical records of 322 patients who had received RT for early-stage NHL of the head and neck at our institute between 1952 and 2000.
  • CONCLUSION: The risk of HNC significantly increased after RT for early-stage NHL.
  • These results suggest that second HNC can be regarded as one of the late complications of RT for NHL of the head and neck.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Lymphoma, Non-Hodgkin / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Radiation induced cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61 [10571202.001]
  • [Cites] Cancer. 1948 May;1(1):3-29 [18867438.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):684-9 [10988046.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 [12694826.001]
  • [Cites] Lancet. 2004 Jan 31;363(9406):345-51 [15070562.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1965 Oct;3(5):353-60 [5839405.001]
  • [Cites] Cancer. 1977 Oct;40(4 Suppl):1786-92 [332330.001]
  • [Cites] Cancer. 1977 Oct;40(4 Suppl):1892-8 [907991.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] Radiat Res. 1982 Oct;92(1):188-200 [7134383.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1986 Jun 25;46(6):811-8 [3786119.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):887-93 [8334642.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;533:60-4 [9657314.001]
  • [Cites] Head Neck. 1999 May;21(3):204-10 [10208662.001]
  • [Cites] Head Neck. 1999 Jul;21(4):346-54 [10376755.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Br J Radiol. 1957 Dec;30(360):626-40 [13489203.001]
  • [Cites] Br Med J. 1959 May 23;1(5133):1329-31 [13651729.001]
  • [Cites] Cancer Res. 1961 Jul;21:717-29 [13779235.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):643-5 [15523441.001]
  • [Cites] Ann Surg Oncol. 2005 Mar;12(3):237-45 [15827816.001]
  • [Cites] Br J Radiol. 2005 Nov;78(935):1028-33 [16249604.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):554-62 [16795069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1265-71 [17637398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1530-6 [18207670.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):498-509 [10653865.001]
  • (PMID = 19591686.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2717106
  •  go-up   go-down


51. Baijal G, Vadiraja BM, Fernandes DJ, Vidyasagar MS: Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly. J Cancer Res Ther; 2009 Apr-Jun;5(2):140-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma of the uterine cervix: a rare case managed novelly.
  • Non-Hodgkin's lymphoma (NHL) of the uterine cervix is exceedingly rare.
  • A biopsy revealed it to be a CD20-positive diffuse large B-cell (DLBCL)-type NHL.
  • She was diagnosed as stage IE after staging work-up, and managed with three courses of rituximab, cyclophosphamide, vincristine, adriamycin, and prednisolone followed by external beam radiotherapy (46 Gy in 23 fractions) by 3D conformal technique.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542675.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Sun XF, Zhen ZJ, Lui DG, Xia Y, He YJ, Wang ZH, Lin JY, Guan ZZ: Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol. Eur J Haematol; 2006 Nov;77(5):365-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
  • OBJECTIVES: This study was designed to evaluate the efficacy and toxicity of the modified B-Non-Hodgkin's Lymphoma (NHL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma.
  • The patients were stratified by risk factors (stage, LDH level and chemotherapy response).
  • All patients were treated with a modified B-NHL-BFM 90 protocol.
  • Of these patients, 22 (40%) had Burkitt's lymphoma (BKL), 22 (40%) had diffuse large B-cell lymphoma (DLBL) and 11 (20%) had anaplastic large T-cell lymphoma (ALCL).
  • At a median follow up of 24 months, the event free survival (EFS) for all patients was 85% +/- 5% with 100% for group R1, 84% +/- 7% for group R2 and 72% +/- 13% for group R3, and most notably, 80% +/- 6% for stage III/IV at diagnosis.
  • CONCLUSIONS: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. China. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Mucositis / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879606.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


53. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA: Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica; 2005 May;90(5):661-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost determinants in aggressive non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: The 5 factors of the International Prognostic Index (IPI) for aggressive non Hodgkin's lymphoma (NHL) age, disease stage, serum lactate dehydrogenase (LDH), performance status, number of extranodal sites) are validated predictors of a patient's survival.
  • DESIGN AND METHODS: Chart data for 374 patients with newly diagnosed stage II-IV aggressive NHL treated between 1993-2001 with CHOP chemotherapy were used.
  • Regression analyses and non-parametric bootstrap tests were performed to determine the significance of prognostic factors.
  • The detailed information presented in this paper is of value for those who need to make cost-effectiveness estimations in NHL, which is a relevant topic, given new treatment modalities that are emerging.
  • [MeSH-major] Health Care Costs. Lymphoma, Non-Hodgkin / economics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / economics. Child. Combined Modality Therapy / economics. Cost-Benefit Analysis. Costs and Cost Analysis. Drug Costs. Female. Fever / epidemiology. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / economics. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Proteins / blood. Netherlands / epidemiology. Prognosis. Radiotherapy, Adjuvant / economics. Retrospective Studies. Risk Factors. Severity of Illness Index. Survival Analysis. Sweating. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921381.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


54. Salem HA, Eissa LA, Rabbie AM, El-Helw LM, El-Gayar AM: Evaluation of some biochemical markers as prognostic factors in malignant lymphomas. Pak J Pharm Sci; 2006 Jul;19(3):219-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the work aimed to investigate the relationship between these levels with B symptoms and disease stage.
  • For this purpose, 43 newly diagnosed patients with malignant lymphoma (12 with Hodgkin's disease (HD) and 31 with Non-Hodgkin's lymphoma (NHL) were selected from Mansoura University Hospital.
  • Among NHL patients, 7 were in stage I/II, 13 in stage III and 14 in stage IV.
  • In addition, 10 NHL patients were presented with B symptoms while, 21 did not.
  • RESULTS: 1-Pre-treatment levels of GAGs, sp55TNF-R and sL-selectin increased significantly in both HD and NHL before treatment as compared to control.
  • Pre-treatment sp55TNF-R levels in both diseases and sL-selectin (only in HD patients) may have a significant value in predicting response to therapy, while GAGs level in both diseases and sL-selectin in NHL patients had a limited value in such prediction.
  • 2- In contrast to sp55TNF-R and sL-selectin, post-treatment GAG levels are thought to be a good sign of remission in both HD and NHL.
  • 3- Serum GAG levels increased significantly before treatment in stages III/IV NHL as compared to stage I/II, so serum GAGs at diagnosis could reflect tumor bulk and the disease activity.
  • CONCLUSION: Pre-treatment sp55TNF-R levels in both HD & NHL and sL-selectin (only in HD patients) could be used as prognostic factor with respect to predicting treatment outcome.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Blood Cell Count. Blood Sedimentation. Female. Glycosaminoglycans / metabolism. Humans. Kidney Function Tests. L-Lactate Dehydrogenase / metabolism. L-Selectin / metabolism. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Tumor Necrosis Factor, Type I / metabolism

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935830.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycosaminoglycans; 0 / Receptors, Tumor Necrosis Factor, Type I; 126880-86-2 / L-Selectin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


55. Rödel S, Engert A, Diehl V, Reiser M: Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study. Leuk Lymphoma; 2005 Dec;46(12):1729-34
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
  • The aim of the present study was to evaluate the feasibility and efficacy of the intensified induction chemotherapy regimen ACOMED for patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Untreated adult patients with aggressive NHL, presenting with Ann Arbour stage II-IV disease or stage I with bulky disease, and with at least one of the following risk factors: age > 60 years, advanced disease, elevated serum lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) performance status >or= 2, presence of extranodal sites of disease and bulky disease, were treated with the ACOMED regimen consisting of 4-6 cycles of adriamycin 25 mg/m(2) i.v. on days 4-5, cyclophosphamide 250 mg/m(2) i.v. on days 1-5, vincristine 2 mg i.v. absolute on day 1, methotrexate 500 mg/m(2) i.v. on day 1 with leucovorin-rescue after 24 h 30 mg/m(2) i.v. and 3 x 15 mg p.o., etoposide 100 mg/m(2) i.v. on days 3-5, dexamethasone 10 mg/m(2) p.o. on days 1-5 and granulocyte colony-stimulating factor support, repeated on day 21.
  • ACOMED followed by involved field radiation presents a highly effective regimen for remission induction and long-term survival in patients with aggressive NHL, and merits further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Survival Analysis. Survivors. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353313.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Hodgkin's disease (HD) in children corresponds to a large degree to HD in adults.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • For practical reasons clinicians generally classify and treat NHL in children as either B-cell or T-cell disease.
  • Lymphoblastic or T-cell NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • Three consecutive regimens have been used to treat B-cell NHL over the past 22 years.
  • Although toxicity has increased with the increased intensity of the treatment regimen, EFS has improved from 25% to 87% for all B-cell NHL.
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Blood Transfusion. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. South Africa. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


57. Moreno M, Sancho JM, Gardella S, Coll R, García O, Gallardo D, Ribera JM: [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients]. Med Clin (Barc); 2010 Jan 30;134(2):72-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients].
  • BACKGROUND AND OBJECTIVES: Non-pegylated liposomal doxorubicin is associated with lower cardiac toxicity than conventional doxorubicin, and for that reason it has been used in the treatment of non-Hodgkin's lymphoma (NHL) in old patients or patients with cardiac disease.
  • The objective of this study was to evaluate the efficacy and safety of chemotherapy schedules including non-pegylated liposomal doxorubicin in patients with NHL.
  • PATIENTS AND METHODS: Retrospective study of NHL patients treated with non-pegylated liposomal doxorubicin in two hospitals.
  • The most frequent histological diagnosis was diffuse large B cell lymphoma (DLBCL, 20 patients).
  • The stage disease at diagnosis was III/IV in 19 (73%) patients whereas 12 (57%) of the 21 patients with DLBCL and grade 3 follicular lymphoma had a high-risk International Prognostic Index.
  • In all cases non-pegylated liposomal doxorubicin was administered as part of the R-COMP schedule (rituximab, cyclophosphamide, vincristin, non-pegylated liposomal doxorubicin and prednisone), in 20 cases (73%) as first-line treatment and in the remaining 6 as salvage therapy.
  • CONCLUSIONS: In this cohort of patients, most of them old and with cardiovascular risk factors, the administration of non-pegylated liposomal doxorubicin as part of R-COMP regimen was effective and safe.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Liposomes. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Rituximab. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19913261.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Liposomes; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


58. Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, Jacobson IM, Rice CM, Dustin LB: Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood; 2008 Feb 01;111(3):1344-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis C virus (HCV) is associated with B-cell lymphoproliferative disorders such as mixed cryoglobulinemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL).
  • These findings lend further support to the notion that specific antigenic stimulation leads to B-cell proliferation in HCV MC and that chronic B-cell stimulation may set the stage for malignant transformation and the development of B-NHL.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Phenotype. Phylogeny. Receptors, Complement 3d / immunology

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Apr 11;416(6881):603-7 [11948342.001]
  • [Cites] Clin Exp Immunol. 2002 May;128(2):353-8 [11985527.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):747-51 [12153160.001]
  • [Cites] Leukemia. 2003 Jan;17(1):260-6 [12529691.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3429-39 [12626604.001]
  • [Cites] Am J Med Sci. 2003 Mar;325(3):135-48 [12640289.001]
  • [Cites] J Hepatol. 2003 May;38(5):642-50 [12713876.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1113-20 [12916862.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] Immunol Rev. 2004 Feb;197:179-91 [14962195.001]
  • [Cites] Clin Immunol. 2004 Nov;113(2):161-71 [15451473.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1711-6 [15284859.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):745-52 [15471561.001]
  • [Cites] Clin Exp Immunol. 1989 Apr;76(1):54-60 [2786780.001]
  • [Cites] J Hepatol. 1991 Nov;13(3):372-4 [1808228.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1490-5 [1383822.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2734-43 [8514881.001]
  • [Cites] J Exp Med. 1993 Dec 1;178(6):1903-11 [8245772.001]
  • [Cites] Immunol Today. 1994 Aug;15(8):367-73 [7916950.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):413-21 [7527818.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] QJM. 1995 Feb;88(2):115-26 [7704562.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):548-52 [7646992.001]
  • [Cites] J Virol. 1995 Dec;69(12):8079-83 [7494326.001]
  • [Cites] Arthritis Rheum. 1995 Dec;38(12):1859-60 [8849361.001]
  • [Cites] JAMA. 1996 Mar 27;275(12):937-9 [8598622.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1288-98 [9028952.001]
  • [Cites] Arthritis Rheum. 1997 Feb;40(2):318-31 [9041944.001]
  • [Cites] Springer Semin Immunopathol. 1997;19(1):99-110 [9266634.001]
  • [Cites] Springer Semin Immunopathol. 1997;19(1):111-29 [9266635.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2381-6 [9516137.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2433-42 [9516143.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3594-601 [9531323.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1679-89 [9802980.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1229-41 [15837810.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6532-9 [15879157.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2257-67 [16041408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):393-400 [16446381.001]
  • [Cites] Nature. 2006 Mar 23;440(7083):540-4 [16525420.001]
  • [Cites] J Virol. 2006 Apr;80(8):3923-34 [16571809.001]
  • [Cites] Leukemia. 2006 Jan;20(1):158-62 [16307019.001]
  • [Cites] Annu Rev Immunol. 2007;25:71-99 [17067278.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Ann Ital Med Int. 1999 Oct-Dec;14(4):288-93 [10638021.001]
  • [Cites] Hepatology. 2000 Feb;31(2):474-9 [10655273.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):211-6 [10861476.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):749-62 [11179248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1166-70 [11158612.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1555-9 [11238090.001]
  • [Cites] Int Immunopharmacol. 2001 Mar;1(3):483-93 [11367532.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):21-9 [11418627.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):253-61 [11438472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10362-7 [11504927.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Hepatology. 2002 Jan;35(1):224-31 [11786980.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2259-61 [11877309.001]
  • [Cites] Arch Pathol Lab Med. 1999 Feb;123(2):119-25 [10050784.001]
  • [Cites] Immunol Today. 1999 Jul;20(7):312-6 [10379049.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1012-20 [10419893.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3647-54 [15191950.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):101-5 [15642884.001]
  • [Cites] Springer Semin Immunopathol. 2005 Mar;26(4):347-62 [15633017.001]
  • [Cites] Lancet Infect Dis. 2005 Apr;5(4):227-36 [15792740.001]
  • (PMID = 17942751.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00219999
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI060561-04; United States / NIAID NIH HHS / AI / R01 AI060561; United States / NCRR NIH HHS / RR / M01 RR000102; United States / NIAID NIH HHS / AI / R01AI60561; United States / NCRR NIH HHS / RR / UL1 RR024143; United States / NCRR NIH HHS / RR / 1UL1 RR024143-01; United States / NCRR NIH HHS / RR / M01-RR00102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Immunoglobulin M; 0 / Receptors, Complement 3d
  • [Other-IDs] NLM/ PMC2214737
  •  go-up   go-down


59. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol; 2006 Oct;17(10):1546-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
  • INTRODUCTION: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
  • METHODS: To confirm this result in a multicenter trial, we randomized patients with aggressive NHL, to receive either eight cycles of CHOP or SHiDo.
  • RESULTS: 129 evaluable patients were randomized to receive either CHOP or SHiDo: median age, 48 years; 62% male; stage III+IV: 73%; age adjusted International Prognostic Index 1/2/3: 21%/52%/27%.
  • CONCLUSION: In this multicenter trial, early intensification with SHiDo did not confer any survival benefit in previously untreated patients with aggressive NHL and was associated with a higher incidence of grades 3/4 toxicity.


60. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH: Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist; 2005 Feb;10(2):138-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
  • We conducted two phase I studies, in non-small cell lung cancer (NSCLC) and in lymphoma, to explore the possibility of intensifying chemotherapy by compressing the delivery of and escalating the dose of standard combination chemotherapy.
  • One study used etoposide and cisplatin chemotherapy in patients with unresectable stage III or IV NSCLC, intensifying chemotherapy by reducing the cycle length.
  • The second study used cyclophosphamide, doxorubicin, vincristine, and prednisone, CHOP chemotherapy, in the treatment of stage II-IV intermediate or immunoblastic high-grade lymphoma, intensifying chemotherapy first by reducing the cycle length and then by escalating the dosages of cyclophosphamide and doxorubicin.
  • Fifty-five patients with NSCLC and 49 with non-Hodgkin's lymphoma (NHL) were enrolled and treated in successive cohorts.
  • In the NSCLC trial, etoposide and cisplatin were intensified by >50%, and in the lymphoma trial, cyclophosphamide was intensified by 270% and doxorubicin was intensified by 87%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Recombinant Proteins. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709216.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone
  •  go-up   go-down


61. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • METHODS: Clinical data of 89 naive patients with NHL of the tonsil, treated from May 1990 to Jan.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • The 5-year overall survival rate was 80%, that of stage I-II patients was 84%.
  • CONCLUSIONS: Most patients with NHL of the tonsil are at early stages, with good prognosis.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


62. Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C, Draisci M, Pizzolo G: Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer; 2005 Aug 1;104(3):555-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients who have aggressive, refractory or recurrent non-Hodgkin lymphomas (NHLs) that are refractory to first-line anthracycline-containing regimens (ACRs) have a dismal outcome.
  • METHODS: Between February 1998 and May 2002, 28 consecutive adult patients (median age, 44 years) with aggressive NHL (B-lineage in 21%, T-lineage in 7%, and Ki-67 percentage > 50 in 82%) were entered on the protocol after they had failed on ACRs (15 patients with refractory disease, 6 patients with stable disease, 5 patients with recurrent disease, and 2 patients in partial remission).
  • Patients characteristics were as follows: Twenty-two patients had Stage III-IV NHL (78.6%), 19 patients had B symptoms (67.8%), 22 patients had extranodal disease (78.6%), 12 patients had bulky mass (42.8%), 18 patients elevated lactate dehydrogenase levels (66%), and 8 patients had high-intermediate/high International Prognostic Index scores (64.3%).
  • CONCLUSIONS: HyperCHiDAM Verona 897 was an effective regimen for patients with aggressive NHL who failed on ACRs, and it allowed patients to undergo subsequent SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy. Salvage Therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Anthracyclines / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Remission Induction. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15959910.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


63. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, Crosta C, Pedrinis E, Bertoni F, Calabrese L, Zucca E: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol; 2005 Mar 20;23(9):1979-83
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
  • PURPOSE: Preliminary results using rituximab in extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients seem to indicate a relevant clinical activity.
  • Aim of the present study is to investigate the efficacy of conventional weekly treatment using rituximab in gastric MALT NHL patients resistant/refractory or not suitable for eradication treatment, and to evaluate the relevance of the t(11; 18)(q21;.
  • PATIENTS AND METHODS: Twenty-seven patients presenting with gastric MALT NHL at any stage, relapsed/refractory to initial treatment or not suitable for eradication were treated with rituximab in a weekly conventional schedule and evaluated for response and relapse.
  • CONCLUSION: Our experience seems to confirm the clinical activity of rituximab in gastric MALT NHL patients resistant/refractory to antibiotics treatment or not presenting with clinical evidence of Helicobacter pylori infection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Female. Helicobacter pylori. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Rituximab. Translocation, Genetic

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Oct 10;23(29):7361-2; author reply 7362-3 [16210674.001]
  • (PMID = 15668468.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


64. Ghersin E, Keidar Z, Eldad DJ, Bar-Shalom R, Fischer D, Halachmi S: Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography. Br J Radiol; 2007 Nov;80(959):e283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography.
  • Positron emission tomography/computed tomography (PET/CT), CT urography (CTU) and antegrade CT pyelography (ACTP) findings of ureteric involvement in non-Hodgkin's lymphoma (NHL) are presented.
  • PET/CT performed for restaging in a patient with a 2-year history of Stage 4 NHL showed increased 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) activity in a distended ureteric segment.
  • Tissue sampling using percutaneous CT-guided biopsy revealed NHL involvement of the ureter.
  • To the best of our knowledge, this is the first report of PET/CT, CTU and ACTP findings of ureteric NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiography. Ureteral Neoplasms / radiography
  • [MeSH-minor] Adult. Fluorodeoxyglucose F18. Humans. Male. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods. Urography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17989329.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Lal A, Bhurgri Y, Vaziri I, Rizvi NB, Sadaf A, Sartajuddin S, Islam M, Kumar P, Adil S, Kakepoto GN, Masood N, Khurshed M, Alidina A: Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas. Asian Pac J Cancer Prev; 2008 Jul-Sep;9(3):453-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
  • OBJECTIVE: The primary objective of this study was to analyze the anatomic distribution, clinical features and outcome of Diffuse large B-cell lymphoma (DLBCL) patients according to the primary site (extranodal vs. nodal) with applicability of International Prognostic Index (IPI).
  • The distribution according to the primary site was: lymph node (N-NHL), 322 cases (58%) of which 145(44%) were stage IV, 76(23%) stage III, 60 (18%) stage II and 47 (15%) stage I.
  • The extra nodal sites (EN-NHL) 235 (42%) cases included gastro-intestinal tract (44%), upper aerodigestive tract (19%), bones (8%), spine (5%), and unusual sites less than 3% each as breast, CNS, testis, lungs and skin.
  • The median survival rate was 4.8 years and 6.3 years in N-NHL and EN-NHL respectively.
  • In the latter this varied greatly depending on the primary site and stage of disease at presentation.
  • In the univariate analysis factors associated with good prognosis were: age less than 60 years, early stage (I-II), extranodal involvement primarily gastric or bone, 0-1 extranodal site, 0-1 performance status, lack of B symptoms and normal LDH level.
  • In the multivariate analysis age, performance status, stage of disease and level of LDH were the main variables predicting overall survival; no nodal or extranodal site maintained their prognostic value.
  • CONCLUSION: Patients with EN-NHL present more frequently with early stage disease then those with N-NHL; overall survival in both groups largely depended on IPI and not on the site of origin of the malignancy.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Analysis of Variance. Biopsy, Needle. Cohort Studies. Confidence Intervals. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Odds Ratio. Pakistan. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004134.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


66. Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H: Socioeconomic Impacts on Survival Differ by Race/Ethnicity among Adolescents and Young Adults with Non-Hodgkin's Lymphoma. J Cancer Epidemiol; 2010;2010:824691

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic Impacts on Survival Differ by Race/Ethnicity among Adolescents and Young Adults with Non-Hodgkin's Lymphoma.
  • Shorter survival has been associated with low socioeconomic status (SES) among elderly non-Hodgkin's lymphoma (NHL) patients; however it remains unknown whether the same relationship holds for younger patients.
  • We explored the California Cancer Registry (CCR), to investigate this relationship in adolescent and young adult (AYA) NHL patients diagnosed from 1996 to 2005.
  • Included in the final analysis were 3,489 incident NHL cases.
  • In the multivariate analyses, all-cause mortality (ACM) was higher in individuals who had later stage at diagnosis (P < .05) or did not receive first-course chemotherapy (P < .05).
  • Overall results were similar for lymphoma-specific mortality.
  • In the race/ethnicity stratified analyses, only non-Hispanic Whites (NHWs) had a significant SES-ACM trend (P < .001).
  • Reduced overall and lymphoma-specific survival was associated with lower SES in AYAs with NHL, although a significant trend was only observed for NHWs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 1997 Nov;8(6):621-8 [9345660.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1409-20 [19496000.001]
  • [Cites] Pediatrics. 2002 Dec;110(6 Pt 2):1328-35 [12456953.001]
  • [Cites] Eur J Haematol. 2004 Nov;73(5):318-24 [15458510.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):73-81 [16170828.001]
  • [Cites] Postgrad Med J. 2005 Nov;81(961):674-9 [16272229.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1105-11 [16505430.001]
  • [Cites] Oncologist. 2007 Jul;12(7):816-24 [17673613.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):183-93 [18027094.001]
  • [Cites] CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31 [18096863.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):917-23 [18464111.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(14):2058-73 [18657412.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):830-5 [18728673.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3231-41 [18937267.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):24-40 [19087093.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3044-51 [19451447.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):703-11 [11562110.001]
  • (PMID = 20652048.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2905919
  •  go-up   go-down


67. Khalifa KA, Alkilani AA, Ismail H, Soliman MA: Evaluation of some biochemical markers as prognostic factors in malignant lymphoma. J Egypt Natl Canc Inst; 2008 Mar;20(1):47-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
  • Non-Hodgkin lymphoma (NHL) is one of the most important malignant diseases worldwide.
  • Cytokines may contribute to the clinical and histopathological alterations of the disease, while CD44, the lymphocyte homing receptor, is a putative determinant of lymphoma dissemination.
  • To assess their value in NHL, the levels of TNF-alpha, IL-2 and sCD44 were measured in patients with different stages of NHL and the relation between these levels and tumor burden, presence of B symptoms and other prognostic criteria of the disease was evaluated.
  • Fifty-two patients with NHL before administration of treatment as well as 20 age- and gender-matched controls were enrolled in this study.
  • LDH and CRP levels were more significantly higher, while albumin level was significantly lower among patients with stage IV as compared to that of patients with stages I/II or III.
  • The levels of TNF-alpha, IL-2 and sCD44 were significantly higher in NHL patients than in controls.
  • In conclusion, the occurrence of B symptoms in NHL may be attributed, at least in part, to high level of TNF-alpha.
  • The increased levels of TNF-alpha IL-2 and sCD44 are associated with high tumor burden and poor prognostic criteria and it is suggest that they can be used as prognostic markers in NHL.
  • [MeSH-major] Antigens, CD44 / blood. Interleukin-2 / blood. Lymphoma, Non-Hodgkin / immunology. Tumor Necrosis Factor-alpha / blood
  • [MeSH-minor] Adult. Biomarkers. C-Reactive Protein / analysis. Female. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847281.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers; 0 / Interleukin-2; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


68. Wu H, Ma Y, Zhu Y, Shen Y, Gu C, Ye Z, Lin H: Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jun;47(6):1110-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma.
  • We investigated the expression of BIRC7, survivin, Bcl-2, Bax, p53 and p170 proteins in 167 cases of non-Hodgkin's lymphoma (NHL) and 10 cases of non-specific lymphadenitis by tissue microarray-based immunohistochemistry.
  • BIRC7 mRNA in three cell lines and 16 cases of NHL were detected by reverse transcriptase-polymerase chain reaction.
  • BIRC7 protein was exhibited in the cytoplasm of cells in 25 (31%) of 80 cases of B-NHLs, 32 (37%) of 87 cases of T-NHLs, and none in non-specific lymphadenitis.
  • The positive rate of BIRC7 was lower than that of survivin in almost all types of NHL with no significant differences, and similar to that of Bcl-2, Bax or p53.
  • There was no correlation of protein expression between BIRC7 and any other detected markers, except p170 in T-NHL (P < 0.001).
  • BIRC7 expression did not correlate with clinic pathologic factors such as sex, age, stage and grade, but overexpression of BIRC7 was positively correlated with aggression of NHL cells (P < 0.05).
  • BIRC7 mRNA expression was approximately consistent with BIRC7 protein in NHL.
  • Our results indicate that the BIRC7 gene might play a role in the development and aggression of NHL and that the inhibition of BIRC7 expression may be important in NHL treatment.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Apoptosis. Gene Expression Regulation, Neoplastic. Inhibitor of Apoptosis Proteins / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / biosynthesis. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Female. Humans. Jurkat Cells. K562 Cells. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840203.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC7 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Neoplasm
  •  go-up   go-down


69. Katsarou O, Touloumi G, Antoniou A, Kouramba A, Hatzakis A, Karafoulidou A: Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients. Haemophilia; 2005 Jul;11(4):360-5
HIV InSite. treatment guidelines - Renal Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rate of PCP (12.0 cases per 1000 person-years) and NHL (5.4 cases per 1000 person-years), the most common causes of AIDS diagnosis in the pre-HAART era, were remarkably reduced in the post-HAART era (both rates: 2.8 cases per 1000 person-years).
  • On the contrary, the corresponding risk for non-AIDS deaths was fourfold increased in the post-HAART period.
  • Of the 38 non-AIDS related deaths in both periods, 13 occurred post-HAART.
  • The predominant cause of non-AIDS mortality in both periods was end-stage liver disease (ESLD) (7 pre- and 4 post-HAART).
  • The rate of non-AIDS related cancers was also increased during the post-HAART period.
  • CONCLUSION: In this haemophilia cohort the risk of AIDS has substantially reduced in the post-HAART period, but the rate of non-AIDS mortality tended to increase.
  • Among haemophilia subjects, due to the high rates of HCV/HIV coinfection, ESLD, the predominant cause of non-AIDS mortality, will become an increasingly important clinical problem.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / epidemiology. Acquired Immunodeficiency Syndrome / etiology. Acquired Immunodeficiency Syndrome / mortality. Adolescent. Adult. Aged. Aged, 80 and over. Cause of Death. Child. Child, Preschool. Disease Progression. Greece / epidemiology. Humans. Incidence. Infant. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / mortality. Male. Middle Aged. Prospective Studies. Risk Factors


70. Ramírez V P, Ocqueteau T M, Alvarez Z M, Bertín C-M P, Lira V P, Bustos C M, Besa de C P: [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy]. Rev Med Chil; 2006 Nov;134(11):1409-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
  • BACKGROUND: Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on the clinical stage.
  • The standard treatment for advanced NHL is 8 cycles of combined chemotherapy, cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
  • AIM: To evaluate the treatment results including overall survival (OS) and event-free survival (EFS) in localized aggressive NHL patients treated at the Pontificia Universidad Católica de Chile, Clinical Hospital.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277854.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


71. Tanaka PY, Pracchia LF, Calore EE: Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil. Int J Hematol; 2006 Nov;84(4):337-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
  • The relative risk of non-Hodgkin's lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV) is elevated compared with the general population.
  • We describe a retrospective study of 78 HIV-infected patients with NHL treated between 1999 and 2006 at the Infectology Institute, a reference center for HIV treatment in São Paulo, Brazil.
  • A univariate analysis showed a significant CR rate in patients with respect to the following factors: no acquired immunodeficiency syndrome (AIDS) diagnosis prior to the lymphoma, disease stage of I to II, and an International Prognostic Index (IPI) of low or low-intermediate risk.
  • Our results provide additional information regarding HIV-related lymphoma in Brazil.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Brazil. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisolone. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118760.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


72. Ho CL, Hsieh AT, Dai MS, Chen YC, Kao WY, Chao TY: Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period. J Chin Med Assoc; 2005 Jan;68(1):11-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the stomach: treatment outcomes for 57 patients over a 20-year period.
  • BACKGROUND: Gastric non-Hodgkin's lymphoma (NHL) is a rare subtype of malignancy, for which no consensus exists about treatment.
  • In this study, the treatment outcomes of gastric NHL in 57 patients were retrospectively evaluated for a period of 20 years at a single institute.
  • METHODS: Clinical stages were classified according to the Ann Arbor staging system: 29 patients were stage 1, 17 stage II, two stage III, and nine stage IV.
  • The 46 stage I/II patients received aggressive, multimodal therapy: 24 of these (group A) were treated with surgery-based management, which included surgery alone (n = 6), surgery + chemotherapy (CT; n = 14), surgery + radiotherapy (RT; n = 2), and surgery + CT + RT (n = 2); 22 patients (group B) did not receive surgery, but received CT alone (n = 11), CT + RT (n = 5), or, in patients with low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, an oral anti-Helicobacter pylori regimen (n = 6).
  • The 11 stage III/IV patients received CT and/or RT with regimens similar to those for stage I/III patients.
  • RESULTS: Except for 1 patient with an initial surgical diagnosis, 56 patients underwent gastric endoscopic examination, which proved that 42 had NHL.
  • The 5-year survival rates for stage 1, II and III/IV patients were 57.2%, 47% and 0%, respectively (p < 0.005).
  • Of the 22 non-surgical patients (group B) who received CT, alone or combined with RT, 14 remained disease-free after a median follow-up of 40 months (range, 4-189 months); 1 patient died because of massive gastric hemorrhage after CT.
  • All stage III and IV patients died after a median survival of 4 months (range, 1-8 months).
  • CONCLUSION: Clinical stage is the most important factor predicting the long-term survival of patients with gastric NHL.
  • In early-stage gastric NHL, non-surgical treatment seems able to achieve the aims of improved long-term survival and, in some instances, cure.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Stomach / pathology. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742857.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


73. Van Hauwaert V, Meers S, Verhoef G, Tousseyn T, Sagaert X, Vermeire S, Rutgeerts P, Van Assche G: Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis. J Crohns Colitis; 2010 Dec;4(6):683-6
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis.
  • A 20-year old man with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) was diagnosed with a rectal non-Hodgkin's lymphoma (NHL) at surveillance endoscopy while being in remission on infliximab therapy.
  • Further staging identified a diffuse large B-cell NHL, EBV negative restricted to the rectal submucosa (stage IA).
  • Until now, there has not been any evidence of an increased risk of NHL in patients with UC nor of an increased risk of lymphoproliferative disorders in IBD patients.
  • Hence, the role of concomitant PSC in the pathogenesis of intestinal NHL is unclear.
  • However, IBD patients treated with purine analogues and with anti-TNF are at risk of NHL, especially hepatosplenic T-cell lymphoma.

  • Genetic Alliance. consumer health - Primary sclerosing cholangitis.
  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [ErratumIn] J Crohns Colitis. 2011 Feb;5(1):79. Tousseyn, Thomas [added]; Sagaert, Xavier [added]
  • (PMID = 21122582.001).
  • [ISSN] 1876-4479
  • [Journal-full-title] Journal of Crohn's & colitis
  • [ISO-abbreviation] J Crohns Colitis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


74. Radić-Kristo D, Planinc-Peraica A, Ostojić S, Vrhovac R, Kardum-Skelin I, Jaksić B: Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics. Coll Antropol; 2010 Jun;34(2):413-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal non-Hodgkin lymphoma in adults: clinicopathologic and survival characteristics.
  • Primary non-Hodgkin lymphomas of gastrointestinal tract (PGI-NHL) are the most common extranodal lymphomas with an increasing incidence.
  • The incidence, clinicopathologic characteristics, treatment and survival were assessed in 39 successive, newly diagnosed PGI-NHL patients (23 male and 16 female) treated at "Merkur" University Hospital.
  • The most common site of PGI-NHL was stomach (n = 29, 74%), followed by small intestine (n = 5, 13%), and colon and rectosigmoid (n = 5, 13%).
  • According to the Ann Arbor classification, 34 (87%) patients had stage IE and IIE, and five patients (12%) stage IIIE and IVE.
  • According to World Health Organization (WHO) classification, 29 (87%) patients had diffuse large B-cell lymphoma (DLCBL), two had mantle cell lymphoma, and seven (18%) had marginal zone B-cell lymphoma-mucosa associated tissue (MALT).
  • In our patients, the major prognostic factor for outcome was the stage of disease.
  • Patients with localized lymphoma (stage IE and IIE) had a significantly longer overall survival: 85% at five years and 65% at ten years.
  • Patients with extended disease (stage IIIE and IVE) had overall survival less than 33%.
  • In conclusion, our patient group was comparable to other literature reports on PGI-NHL patients according to clinicopathologic characteristics.
  • Disease stage and LDH were the only parameters that had a statistically significant effect patient survival.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Colonic Neoplasms / epidemiology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Female. Humans. Intestinal Neoplasms / epidemiology. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Rectal Neoplasms / epidemiology. Rectal Neoplasms / mortality. Rectal Neoplasms / pathology. Retrospective Studies. Sigmoid Neoplasms / epidemiology. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Survival Rate. Young Adult


75. Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R: Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol; 2010 Jun;27(2):310-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma: experience from a tertiary care center in North India.
  • Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL).
  • We undertook a retrospective case record study to determine the clinico-laboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL).
  • DLBCL, constituting 59.3% of all NHL cases, was the predominant subtype.
  • A total of 49.3% of patients had Ann Arbor Stage IV disease.
  • Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.
  • [MeSH-major] Cancer Care Facilities. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Protocols. Child. Female. Humans. India / epidemiology. Male. Middle Aged. Retrospective Studies. Survival Rate / trends. Tertiary Prevention. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350421.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA: Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood; 2008 Jun 1;111(11):5359-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.
  • To investigate their importance in non-Hodgkin lymphoma (NHL), we enumerated Treg cells in peripheral blood mononuclear cells (PBMCs) and involved tissues from 30 patients.
  • CD25(+)FoxP3(+)CD127(low)CD4(+) Treg cells were increased markedly in PBMCs (median = 20.4% CD4 T cells, n = 20) versus healthy controls (median = 3.2%, n = 13, P < .001) regardless of lymphoma subtype, and correlated with disease stage and serum lactate dehydrogenase (R(s) = 0.79, P < .001).
  • T-cell hyporesponsiveness was reversed by depleting CD25(+) cells, or by adding anti-CTLA-4, supporting the view that Treg cells explain the systemic immunosuppression seen in NHL.
  • We conclude that NHL cells are powerful inducers of Treg cells, which may represent a new therapeutic target.
  • [MeSH-major] Lymphoma, Non-Hodgkin / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocytes, Regulatory / immunology. Tumor Escape / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Humans. Lymphocyte Activation / immunology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305220.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Huang WT, Chuang SS, Huang CC, Lu CL, Eng HL: Primary diffuse large B-cell lymphoma of the gallbladder with cholelithiasis masquerading as acute cholecystitis: case report and literature review. N Z Med J; 2007;120(1251):U2470
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B-cell lymphoma of the gallbladder with cholelithiasis masquerading as acute cholecystitis: case report and literature review.
  • Primary non-Hodgkin lymphoma (NHL) of the gallbladder (GB-NHL) is exceedingly rare.
  • He received cholecystectomy under the preoperative diagnosis of acute cholecystitis with septic shock, while pathologic examination revealed cholelithiasis and diffuse large B-cell lymphoma without acute inflammation.
  • Staging procedures revealed a stage IE tumour and the patient received adjuvant radiotherapy.
  • A literature review revealed 20 cases of GB-NHL.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma seems to carry a longer survival than non-MALT lymphomas.
  • [MeSH-major] Cholecystitis, Acute / diagnosis. Cholelithiasis / diagnosis. Cholelithiasis / etiology. Gallbladder Neoplasms / complications. Gallbladder Neoplasms / diagnosis. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cholecystectomy. Diagnosis, Differential. Fatal Outcome. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome


78. Huang HQ, Peng YL, Cai QQ, Lin XB, Li YH, Xia ZJ, Lin TY, Sun XF, Zhang L, Xu GC, He YJ, Jiang WQ, Guan ZZ: [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):577-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
  • OBJECTIVE: To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of non-Hodgkin's lymphoma (NHL).
  • METHODS: Three hundred and ninety two patients with NHL were treated by THP containing regimen with or without involved field radiotherapy.
  • B-cell and T/NK cell NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large B cell lymphoma and 12.5% of peripheral T cell lymphoma.
  • 92.6% of the patients were ECOG < 1, 63.2% in stage I + II, 84.7% with IPI score 0 - 2 and 25% with B symptoms, 93.9% (368/392) of the patients received CTOP (containing THP) regimen chemotherapy and among them 28.5% (112/392) plus involved field radiotherapy.
  • CONCLUSION: The efficacy of THP based regimen CTOP for the treatment of aggressive NHL is promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532963.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


79. Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST: High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol; 2009 Sep;20(9):1543-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
  • BACKGROUND: Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in lymphoma staging is still being accumulated and current staging is based primarily on CT.
  • This study aims to compare the value of PET/CT over conventional CT and bone marrow biopsy (BMB) in the initial evaluation of patients with lymphoma.
  • RESULTS: Among the 122 patients, 101 had non-Hodgkin's lymphoma (NHL) and 21 had Hodgkin's lymphoma (HL).
  • Compared with conventional CT, PET/CT upstaged 21 (17%) cases [B-cell non-Hodgkin's lymphoma (B-NHL), 12; T-cell non-Hodgkin's lymphoma (T-NHL), 3; HL, 6].
  • Of note, all 13 with early-stage HL had negative PET/CT scan and BMB.
  • In NHL, all 17 cases of T-NHL had concordant PET and BMB results.
  • In patients with aggressive B-NHL, BMB and PET/CT agreed in 58 patients (92%) and disagreed in five (8%), while the corresponding rates in indolent B-cell lymphoma were 14 (67%) and seven patients (33%), respectively.
  • Except for indolent B-NHL, our data show that PET scans have a good overall NPV in excluding lymphomatous bone marrow involvement.
  • This is particularly true of early-stage HL, suggesting that BMB may be safely omitted in this group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474116.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA: Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood; 2006 Jun 15;107(12):4623-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
  • A single center, prospective clinical trial was conducted evaluating 2 cycles of induction high-dose chemotherapy for adults younger than 65 years of age with aggressive non-Hodgkin lymphoma (NHL) and 2 to 3 Age-Adjusted International Prognostic Index risk factors.
  • From June 1998 to August 2004, 55 patients aged 20 to 63 years (median 44 years) were accrued, 51 (92%) of whom had diffuse large B-cell NHL.
  • Poor prognostic factors included stage 4 (n = 46), elevated lactate dehydrogenase (LDH; n = 47), Eastern Cooperative Oncology Group (ECOG) performance status 2 to 4 (n = 43), bulky mass more than 10 cm (n = 34), and marrow involvement (n = 16).
  • In conclusion, CHOP-DICEP-BEAM is feasible and gave encouraging EFS and OS for patients with poor-prognosis aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Male. Melphalan / administration & dosage. Middle Aged. Podophyllotoxin / administration & dosage. Prednisone / administration & dosage. Prognosis. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Survival Rate. Transplantation, Autologous. Vincristine / administration & dosage


81. Zhai LZ, Xiao J, Fu XH, Ye S, Guo CC, Huang JJ, Tian Y, Lin HL, Lin TY: [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma: a report of 90 cases]. Ai Zheng; 2009 Jul;28(7):734-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma: a report of 90 cases].
  • BACKGROUND AND OBJECTIVE: Mucosa-associated lymphoid tissue lymphoma is a histological type of marginal zone non-Hodgkin's lymphoma (NHL).
  • METHODS: Clinical data of 90 pathologically confirmed mucosa-associated lymphoid tissue lymphoma patients, treated from December 1997 to February 2007, were analyzed.
  • RESULTS: Of the 90 patients, 23 (25.6%) had gastric lymphoma and 67 (74.4%) had non-gastric lymphoma, with a median age of 52 (range, 13-77); 75 (83.3%) had stage I-II disease and 15 (16.7%) had stage III-IV disease; 31 (34.4%) had multiple organ involvement and 40 (44.4%) had nodal involvement.
  • The percentage of nodal involvement was significantly higher in non-gastric group than in gastric group (P=0.040).
  • In non-gastric lymphoma group, IPI score was an independent prognostic variable of overall survival (P=0.023).
  • CONCLUSIONS: Mucosa-associated lymphoid tissue lymphoma should be considered as a kind of disseminated indolent lymphoma.
  • The patients with non-gastric lymphoma are likely to have nodal involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell, Marginal Zone. Stomach Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624901.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


82. Gonzalez QH, Heslin MJ, Dávila-Cervantes A, Alvarez-Tostado J, de los Monteros AE, Shore G, Vickers SM: Primary colonic lymphoma. Am Surg; 2008 Mar;74(3):214-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • Surgical resection of primary colonic lymphoma can be an important therapeutic tool.
  • From January 1990 to June 2002, a total of 15 patients with primary colonic lymphoma were identified from the tumor registry at University of Alabama at Birmingham and retrospectively reviewed under Institutional Review Board approved protocol.
  • Preoperative diagnosis of lymphoma was made in 13 patients (87%) with colonoscopy and biopsy.
  • According to the clinical classification of primary non-Hodgkin lymphoma (NHL) of the gastrointestinal tract (Lugano, 1993) all patients corresponded to stage IE.
  • Surgical resection of localized, primary colonic lymphoma provides excellent local disease control and should be considered a primary treatment option.
  • The role of chemotherapy remains controversial depending on the grade, stage, and extension of residual disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Colectomy / methods. Female. Humans. Length of Stay / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376684.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Pan ZH, Huang HQ, Lin XB, Xia YF, Xia ZJ, Peng YL, Cai QQ, Lin TY, Jiang WQ, Guan ZZ: [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases]. Ai Zheng; 2005 Dec;24(12):1493-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
  • BACKGROUND & OBJECTIVE: Nasal-type NK/T-cell non-Hodgkin's lymphoma (NHL) is a unique subtype with the manifestation of local necrosis, infection and fever.
  • The efficacy of chemotherapy alone is unsatisfactory; while radiochemotherapy plays some roles in the management of NK/T-cell lymphoma (NK/TCL).
  • RESULTS: Of the 93 patients, 75 (80.6%) were in stage I-II, and 18 (19.4%) were in stage III-IV.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351799.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


84. Lascaux AS, Hemery F, Goujard C, Lesprit P, Delfraissy JF, Sobel A, Lepage E, Lévy Y: Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses; 2005 Mar;21(3):214-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas.
  • The influence of HAART on the survival of patients with AIDS-related lymphoma (ARL) was evaluated.
  • Patients received uniformly the same chemotherapy regimen according to CD4 cell counts at NHL diagnosis:, patients with CD4 cells below or above 100 cells x 10(6)/liter received CHOP or ACVBP regimens, respectively.
  • Ann Arbor stage 3-4 was noted in 60 patients (82%) and bone marrow or meningeal involvement was present in 13 (17%) and 12 (16%) patients, respectively.
  • There was no statistical significant differences in lymphoma extensive stage, presence of B symptoms, meningeal involvement, CD4 cell count at diagnosis, prior AIDS events, or chemotherapy regimens between the two groups.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Female. Humans. Male. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795527.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Schütt P, Zimmermann K, Derks C, Ebeling P, Welt A, Poser M, Hense J, Metz K, Anhuf J, Sandmann M, Neise M, Moritz T, Stuschke M, Niederle N, Seeber S, Nowrousian MR: Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Mar;135(3):459-66
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
  • INTRODUCTION: Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL).
  • METHODS: We conducted a study using a sequential combination chemotherapy with a reduced cumulative dose of anthracyclines in younger patients with good-prognosis aggressive NHL.
  • Consolidating involved-field irradiation was applied in patients with stage I/II, bulky disease, or localized residual lymphoma.
  • [MeSH-major] Anthracyclines / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal / toxicity. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Remission Induction. Rituximab. Survival Analysis. Survivors. Vincristine / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758815.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


86. Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F: Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med; 2008 Sep;8(3):141-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
  • Herein, we set out to determine whether circulating fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and platelet-derived growth factor-beta (PDGF-beta) decrease after radiotherapy in patients with non-Hodgkin lymphomas (NHLs) and if so, whether their decrease correlates with age, tumour histotype and stage, and radiation dose.
  • These levels were correlated both reciprocally and with age, histotype, stage and radiation dose.
  • Haemoglobin levels did not decrease after radiotherapy, while FGF-2, VEGF, HGF and PDGF-beta levels did not correlate with age, NHL stage and histotype.
  • [MeSH-major] Cytokines / blood. Lymphoma, Non-Hodgkin / radiotherapy. Neovascularization, Pathologic
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791686.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


87. Shi YX, Peng RJ, Lin SX, Wu QL, Lin TY, Sun XF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ: [A survival of 103 cases of T-cell non-Hodgkin lymphoma]. Zhonghua Nei Ke Za Zhi; 2007 Dec;46(12):1000-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A survival of 103 cases of T-cell non-Hodgkin lymphoma].
  • OBJECTIVE: T-cell non-Hodgkin lymphoma was heterogeneous and relatively high incident in our country.
  • This study was to analyze clinical feature and survival of T-NHL.
  • METHODS: Records of 103 cases with T-NHL, treated from Dec 1998 to Dec 2004 in Cancer Center of Sun Yat-sen University, were retrospectively analyzed.
  • Kaplan-Meier analysis discovered that age > 60 years, advanced stage (stage II, IV), extranodal involvement, bulky disease, B symptom, performance status (PS) > or = 2, LDH elevated, hypoalbumin, median-high IPI (IPI > or = 2) were bad to prognosis, but Cox regression found that age > or = 60 years, performance status (PS) > or = 2S, hypoalbumin were the independent bad factors to prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478916.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


88. Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G: FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging; 2008 Mar;52(1):9-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
  • AIM: Identification of bone marrow disease (BMD) is a crucial step in the diagnostic work-up of patients with lymphoma.
  • In lymphoma staging, bone marrow biopsy (BMb) is considered as the gold standard, despite its limitations.
  • The aim of this study was to compare the usefulness of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) vs BMb in the detection of BMD in patients with Hodgkin's disease (HL) or aggressive non-Hodgkin's lymphoma (NHL) and its impact on therapy.
  • METHODS: A total of 194 consecutive patients with malignant lymphoma were referred for staging.
  • The clinical stage was defined according to the Ann Arbor classification by means of contrast enhanced computed tomography (CT), BMb and whole body FDG-PET/CT scan.
  • There were no significant differences in PET and BMb accuracy between the HL and the NHL patients.
  • [MeSH-major] Bone Marrow Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow / radionuclide imaging. Child. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235420.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


89. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • High-dose sequential chemotherapy (HDSC) can intensify the conventional salvage treatment and improve the outcome of ASCT by maximal debulking of the tumor load with the use of non-cross resistant drugs, each at their maximal tolerated doses.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • Factors predicting OS were response to conventional salvage therapy and stage prior to salvage therapy.
  • Three prognostic subgroups were defined according to the score determined by stage prior to initiation of salvage chemotherapy, remission duration prior to salvage (refractory/early relapse vs. late relapse) and response to salvage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


90. Anichini A, Mortarini R, Romagnoli L, Baldassari P, Cabras A, Carlo-Stella C, Gianni AM, Di Nicola M: Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines. Blood; 2006 Jan 15;107(2):602-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines.
  • The unfavorable clinical evolution in indolent non-Hodgkin lymphomas suggests defective control of neoplastic growth by the immune system.
  • To address this issue, we evaluated phenotype, function, and maturation profile of CD4(+) and CD8(+) T cells from peripheral-blood, lymph nodes, or bone marrow of patients with B-cell non-Hodgkin lymphoma (NHL) at diagnosis.
  • These results suggest impaired T-cell differentiation to effector stage in patients with B-cell NHL, but indicate that T-cell responsiveness to gammac cytokines is retained, thus allowing to promote generation of antitumor T cells for immune intervention.
  • [MeSH-major] Cell Differentiation. Cytokines / immunology. Lymphoma, B-Cell / immunology. Receptors, Interleukin-7 / immunology. T-Lymphocytes / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adult. Bone Marrow / immunology. Bone Marrow / pathology. Humans. Interferon-gamma / immunology. Interleukin Receptor Common gamma Subunit. Lymph Nodes / cytology. Lymph Nodes / immunology. Lymph Nodes / pathology. Th2 Cells / immunology. Th2 Cells / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150945.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / IL2RG protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / Receptors, Interleukin-7; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


91. Balogun TM, Omodele FO, Olaiya MA: Primary lymphoma of the testis in remission for more than ten years: a case report. West Afr J Med; 2009 Nov-Dec;28(6):388-90
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the testis in remission for more than ten years: a case report.
  • BACKGROUND: Primary testicular lymphoma is a unique, rare and aggressive extra nodal non-Hodgkins Lymphoma (NHL).
  • It is the most common testicular tumour in males between 60 and 80 years old OBJECTIVE: To report a case of primary testicular lymphoma in a young man who has done very well on surgery and chemotherapy.
  • Histology revealed intermediate grade nodular NHL of the right testis.
  • CONCLUSION: Primary testicular lymphoma is a rare and unique neoplasm of the testis and is most commonly seen in men over the age of 60, but should be considered in the differential diagnosis of testicular tumours in younger age groups.
  • It is curable in early stage with appropriate multimodalities of management.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Diseases / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Orchiectomy. Remission Induction. Spermatic Cord / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486099.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


92. Zhang HY, Guan ZZ, Wang B, Huang HQ, Xia ZJ, Lin TY: [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 May;30(5):381-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
  • OBJECTIVE: To investigate the relationship of clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma (DLBCL).
  • The influencing factors such as age, stage, serum level of lactate dehydrogenase (LDH) and bulky disease were analyzed retrospectively in terms of the response.
  • RESULTS: In the patients with previously untreated aggressive B-NHL, the combination of rituximab with chemotherapy achieved an overall response rate (ORR) of 90.7% and CR of 69.8%, while in the patients with relapsed disease, that was 80.8% (ORR) and 30.8% (CR).
  • The disease stage (P = 0.046), serum lactate dehydrogenase (LDH) (P = 0.024), physical status (P = 0.009) and bulky disease (P = 0.013) were found to be unfavorable factors for the immunochemotherapy.
  • CONCLUSION: The immunochemotherapy regimen (rituximab plus chemotherapy) can improve the response rate and CR rate without significant increase in toxicity in patients with diffuse large B-cell lymphoma.
  • The advanced stage, high serum LDH level, relapsed disease, bulky disease and negative Bcl-2 expression are unfavorable factors affecting the therapeutic efficacy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Inhibitor of Apoptosis Proteins. L-Lactate Dehydrogenase / blood. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Remission Induction. Retrospective Studies. Rituximab. Survival Rate. Vincristine / therapeutic use. Young Adult. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953841.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


93. Parvez T, Behani A, Ali A: Primary gastric lymphoma. J Coll Physicians Surg Pak; 2007 Jan;17(1):36-40
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma.
  • OBJECTIVE: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA).
  • RESULTS: All cases were Non-Hodgkin Lymphoma (NHL).
  • There were 10 (45%) patients with stage II, and 6 (27%) patients each with stage III and IV diseases.
  • Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%).
  • CONCLUSION: PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Saudi Arabia. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204218.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


94. Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol; 2006 May;17 Suppl 4:iv18-24
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
  • BACKGROUND: The prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) relapsing or progressing after front-line therapy remains poor.
  • We evaluated the clinical activity, toxicity and mobilizing capacity of a new salvage regimen, which combines gemcitabine and oxaliplatin with ifosfamide and rituximab (R-GIFOX) in patients with relapsed and refractory CD20(+) NHL.
  • RESULTS: Fourteen patients (median age 63 years, range 37-78 years) with relapsed (n = 9) or primary progressive (n = 5) aggressive (diffuse large cell, mantle cell, follicular G3), advanced (stage IV 71%), poor risk (IPI 3-5 50%) NHL were accrued in this pilot study.
  • Molecular remissions were documented in two patients with mantle cell NHL.
  • CONCLUSIONS: Based on the results of this pilot study, we conclude that the R-GIFOX regimen is feasible, tolerable, effective and able to mobilize peripheral stem cells in patients with relapsed and refractory aggressive NHL.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702180.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


95. Laudi N, Arora M, Burns LJ, Miller JS, McGlave PB, Barker JN, Ramsay NK, Orchard PJ, Macmillan ML, Weisdorf DJ: Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant; 2005 Feb;11(2):129-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
  • Autologous hematopoietic stem cell transplantation (AHSCT) in low-grade non-Hodgkin lymphoma (NHL) can result in a prolonged remission, although most patients eventually relapse and die of their disease.
  • We report long-term outcomes of AHSCT for patients with relapsed low-grade NHL.
  • Between May 1983 and 2001, 67 patients with relapsed or refractory stage III and IV low-grade NHL received an AHSCT at the University of Minnesota at a median of 2.3 years (range, 0.4-15.2 years) after diagnosis.
  • At transplantation, 62 patients (92%) were in complete remission (CR) (6%) or partial remission (PR) (86%); 5 (8%) had resistant disease; and 9 (14%) had transformed to a higher-grade NHL.
  • We present mature follow-up data (median follow-up, 8 years; range, 2-18 years) of patients undergoing AHSCT for relapsed low-grade NHL and demonstrate extended OS and PFS.
  • Recurrent lymphoma after AHSCT remains the major problem, and prolonged survival is further tempered by a significant risk of post-transplantation second malignancies, including myelodysplastic syndrome/acute myeloid leukemia and solid tumors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / mortality. Male. Middle Aged. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / mortality. Recurrence. Risk Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682074.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Matalliotakis I, Cakmak H, Fragouli Y, Zervoudis S, Neonaki M, Arici A: Association of endometriosis with family history of non-Hodgkin's lymphoma: presentation of 10 cases. J BUON; 2009 Oct-Dec;14(4):699-701
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of endometriosis with family history of non-Hodgkin's lymphoma: presentation of 10 cases.
  • PURPOSE: Women with endometriosis have been reported to be at increased risk of developing non-Hodgkin's lymphoma (NHL).
  • The purpose of this article was to investigate the familial risk of NHL in women with endometriosis.
  • We report on 10 cases with endometriosis and positive family history of NHL.
  • Ten cases of endometriosis having first-degree relatives with NHL are reported.
  • RESULTS: We found no case with endometriosis and NHL.
  • In contrast, we found 10/405 (2.5%) women with endometriosis and first-degree relatives with NHL.
  • The stages of endometriosis were: stage II (n=4), stage III (n=2) and stage IV (n=4).
  • All of these patients had first-degree relatives with a history of NHL.
  • Five had mothers with NHL, 5 had fathers and one had a sister.
  • CONCLUSION: These cases could suggest a link between a family history of NHL and subsequent development of endometriosis in the first-generation women.
  • Moreover, there was no evidence of association between endometriosis and NHL.
  • [MeSH-major] Endometriosis / etiology. Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148465.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


97. [Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma]. Akush Ginekol (Sofiia); 2010;49(5):64-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma].
  • Affected lymph nodes in cervical cancer is different and depends on the stage and histological type of tumor (squamous and adenocarcinoma) and is an important prognostic factor.
  • Malignant non-Hodgkin's lymphoma populations (NHL) originale from the lymph organs and from their populations downstream lymphoid Stem cell to mature lymphocytes that have opportunities for transformation and proliferation.
  • Recognition of different types of NHL is a complex diagnostic process, in which besides routine cytological and histological methods is requiring the use of immunohistological, imaging and invasive methods.
  • We present the random case developed cervical cancer and malignant lymphoma.
  • [MeSH-major] Lymphoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21268405.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


98. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • MATERIALS AND METHODS: We have retrospectively reviewed records of NHL patients registered, from January 2003 to July 2007 to analyze HIV-associated NHL.
  • RESULTS: Seven cases of HIV-associated NHL cases were identified.
  • Three cases had nodal lymphoma and four had extra nodal lymphoma.
  • No primary CNS (PCNSL) lymphoma was seen.
  • Six cases had high-grade NHL.
  • HIV infection was diagnosed as part of NHL work-up in five patients.
  • CONCLUSIONS: These NHL are of higher grade and advanced stage.
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


99. Li Y, Yang Z, Guo Y, Yu J, Lu C, Bai H, Zhu P: [Contrast-enhanced multislice CT features and predominant anatomic distribution of mediastinal malignant lymphoma]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Oct;24(5):1045-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contrast-enhanced multislice CT features and predominant anatomic distribution of mediastinal malignant lymphoma].
  • The objective of this study was to investigate the specific contrast-enhanced MSCT features and predominant anatomic distribution of mediastinal malignant lymphoma.
  • Nine cases of Hodgkin Disease (HD) and 22 cases of Non-Hodgkin Disease (NHL) were included.
  • The enlarged nodes were found to be homogeneous (HD 72.7%, NHL 88.9%) and partly homogeneous with necrosis (HD 27.3%, NHL 11.1%).
  • HD involved predominantly the lymph nodes in the areas of 2R (77.8%), 3 (55.6%), 4R (88.9%), 4L (55.6%), 5 (66.7%), 6 (55.6%), 7 (66.7%) and 10R (55.6%), while NHL often involved the areas of 2R (68.2%), 3 (54.5%) 4R (59.1%), 4L (50%), 5 (54.5%), 6 (54.5%), 7 (54.5%) and 8 (50%).
  • Mediastinal malignant lymphoma had some characteristic manifestations and predominant anatomic distribution shown on contrast-enhanced MSCT, which can provide imaging evidences for diagnosis and for determining the tumor stage.
  • [MeSH-major] Hodgkin Disease / radiography. Lymph Nodes / pathology. Lymphoma, Non-Hodgkin / radiography. Mediastinal Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Female. Humans. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027693.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


100. Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD, Cancer and Leukemia Group B Study 9153: Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer; 2006 Dec 15;107(12):2817-25
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
  • BACKGROUND: The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL).
  • METHODS: For this multicenter, single-arm, Phase II study, 44 patients with treatment-naive, stage III or IV, indolent NHL (International Working Formulation subtypes A, B, and C) were enrolled.
  • CONCLUSIONS: 2-CdA is an active, well-tolerated therapy for patients with untreated, indolent NHL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cladribine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 17120198.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA47555; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down






Advertisement